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INTRODUCTION 
 Rhinosinusitis is defined as the inflammation of nasal and paranasal 
sinus mucosa and is associated with mucosal alterations ranging from 
inflammatory thickening to gross nasal polyp formation. Rhinosinusitis is a 
common disorder affecting approximately 20% of the population at some time 
of their lives. It has been estimated to affect approximately 23 million patients 
(4% of adult population)in the United States each year6.  A recent survey 
reported that 11% of adults recalled a health professional’s diagnosis of 
sinusitis.1 
 The International Classification of Diseases divides Rhinosinusitis into 
acute and chronic forms according to the duration of symptoms. Acute 
rhinosinusitis(ARS) lasts upto 12 weeks with complete resolution of symptoms, 
whereas Chronic Rhinosinusitis (CRS) persists beyond 12 weeks.1,83,84 
 The inflammation of the nasal and sinus mucosa may be due to 
microorganisms (bacteria and fungi), allergic and non allergic immunological 
inflammation, and noninfectious, non immunological causes. The subset of 
rhinosinusitis cases where the etiological role of fungi is proven or is 
considered to be important (due to its isolation from tissue biopsy samples) is 
referred to as fungal rhinosinusitis (FRS). Fungal sinusitis is being increasingly 
recognized in persons of all age groups, resulting in great socioeconomic 
effects. Previously, 5-15% of cases of chronic rhino sinusitis cases were 
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thought to be of fungal etiology. However, after the claim of fungus to be the 
etiological agent in majority of cases of CRS by Ponikau et al, 1999, the impact 
of fungal rhinosinusitis seems to be tremendous. 5 
 Fungal rhinosinusitis can range from the benign localized fungal 
colonisation to the extremely aggressive acute invasive form having a very 
broad spectrum of disease. Fungal sinusitis causes significant physical 
symptoms, severe quality of life impairment, and can substantially impair daily 
functioning. The economic effect is also huge. As the incidence of chronic 
fungal rhinosinusitis has increased over the last decade, the economic effect is 
expected to be more. The patients have high morbidity and even may have high 
mortality especially those having acute invasive fungal rhinosinusitis. 22 
 Our knowledge about the epidemiology and medical mycology of the 
disease remains incomplete and subject to newer findings and research despite 
recognition of FRS as a serious disease entity for more than two centuries, The 
disease is often neglected and misdiagnosed especially in developing countries 
like India, where FRS is one among the neglected diseases. Few studies have 
been done to quantitate the impact of fungi in the pathogenesis of sinusitis in 
India and fewer in Tamilnadu. This study was conducted in a tertiary care 
hospital to evaluate the occurrence of fungi as  etiology for the occurrence of 
rhinosinusitis in patients admitted with a radiological diagnosis of 
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rhinosinusitis and undergoing diagnostic and therapeutic endoscopic 
procedures for  the same. 
 Resistance to antifungals is not that commonly encountered problem .It 
is an emerging concern as resistance of Aspergillus spp to standard antifungals 
have been noted and reported. Hence, anti fungal susceptibility testing is 
advised for isolates causing FRS, particularly for invasive forms, chronic 
granulomatous forms and those occurring in immunocompromised. Anti fungal 
susceptibility testing is not as simple as that of bacteria. It is tedious and costly 
and not routinely attempted in all laboratories .So, an attempt has been made in 
this study to try and compare different methods of susceptibility testing for 
filamentous fungi. 
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AIM OF THE STUDY 
 To isolate the fungi causing chronic fungal rhinosinusitis. 
 To identify and speciate the fungi. 
 To categorise the types of fungal sinusitis. 
 To assess the  risk factors favouring fungal involvement of paranasal 
sinuses. 
 To study the susceptibility pattern of the fungal isolates to standard anti 
fungal drugs. 
 To compare different methods of susceptibility testing for the fungal 
isolates. 
 
. 
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REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVES 
 The identification and documentation of fungus as a cause of chronic 
rhinosinusitis in patients goes way back to the 18th century when Plaignaud in 
1791 described ‘fungus tumor’ in the maxillary sinus of a 22-year-old soldier6. 
Then slowly fungus has gained importance as a common cause of sinusitis and 
various people have documented fungi in sinusitis. In a controversial article, 
Ponikau et al, 1999, using novel diagnostic techniques, demonstrated the 
presence of fungi and eosinophils in 96% of chronic fungal sinusitis .5If their 
findings are true, this will effectively mean that nearly all patients of CRS have 
a fungal etiology. 
CATEGORISATION OF FUNGAL SINUSITIS 
 Though a lot of controversies surround the categorization of FRS, most 
commonly accepted system divides FRS into two categories : Invasive and 
noninvasive depending on the invasion of fungi across mucous membrane. 
 Invasive FRS is subcategorized as into three groups: acute invasive 
(fulminant), granulomatous invasive, and chronic invasive. Noninvasive FRS is 
also further subcategorised as into three groups: Localized colonization, fungal 
ball (sinus mycetoma), and eosinophil related FRS (including allergic fungal 
rhinosinusitis, eosinophilic fungal rhinosinusitis).6 
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1. INVASIVE FUNGAL RHINOSINUSITIS  
A. ACUTE INVASIVE (FULMINANT) FRS:  
 Commonly caused by members of the class Zygomycetes or by 
Aspergillus spp. This disease occurs more often in the immunocompromised 
patients,22,25,27 and associated with a mortality rate exceeding 50%. The disease 
is characterized by a predominant vascular invasion .7 
B .GRANULOMATOUS INVASIVE FRS: 
 This disease has been described primarily in Sudan, India, Pakistan and 
Saudi Arabia, and rarely in the United States, and is characterized by a time 
course of more than 12 weeks.7,9,56 The entity presents with an enlarging mass 
in the cheek, orbit, nose, and paranasal sinuses in immunocompetent hosts.88  
3. CHRONIC INVASIVE FRS:  
 Chronic invasive FRS is a slowly destructive process that most 
commonly affects the ethmoid and sphenoid sinuses but may involve any 
paranasal sinus. The entity is usually seen in the patients having diabetes 
mellitus or on corticosteroid treatment.55,56,57,89 Cultures of tissue are positive  
in >50% of cases and A. fumigatus is the most common agent isolated6. 
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2. NONINVASIVE FRS: 
A. LOCALIZED FUNGAL COLONIZATION: 
 This disease entity refers to the asymptomatic colonization of mucous 
crusts within the nasal cavity by fungi, often in patients who had previous sinus 
surgery.10  
B. SINUS FUNGAL BALL/ MYCETOMA/ASPERGILLOMA OF 
 SINUSES:  
 Sinus fungal ball is described as the presence of noninvasive 
accumulation of dense conglomeration of fungal hyphae in one sinus cavity95, 
usually the maxillary sinus, though the disease may affect other sinuses or 
rarely multiple sinuses.11,90The disease is defined by the following criteria: 
Radiological evidence of sinus opacification with or without radiographic 
heterogenecity, mucopurulent cheesy or clay-like materials within the sinus, a 
dense conglomeration of hyphae separate from the sinus mucosa ,nonspecific 
chronic inflammation of the mucosa, no predominance of eosinophils or 
granuloma or allergic mucin, no histopathological evidence of fungal invasion 
of mucosa.11,90 
C. EOSINOPHIL RELATED FRS: 
i. ALLERGIC FUNGAL RHINOSINUSITIS (AFRS): 
 Bent and Kuhn proposed five diagnostic criteria for the entity of AFRS: 
Type I hypersensitivity, nasal polyposis, characteristic findings on CT 
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scan, presence of fungi on direct microscopy or culture, and allergic mucin 
containing fungal elements without tissue invasion.4 The ‘peanut-butter’ 
or‘cottage-cheese’ like mucin evacuated from sinuses of patients of AFRS is 
indistinguishable from the mucoid impactions of patients with ABPA. The 
adjacent sinus mucosa has a mixed cellular infiltrate of eosinophils, plasma 
cells, and lymphocytes.7,92However, the most important aspect in the concept of 
AFRS is the allergy to fungi. It is believed that fungal allergens elicit Type-I 
and possibly Type–III mediated mucosal inflammation in the absence of 
invasion in an atopic host.13,93 The  clinical examination should consider 
historical and physical stigma of atopy (hay fever, asthma, eczema, inhalant 
allergy), as well as nasal polyposis6,2. 
ii. EOSINOPHILIC FUNGAL RHINOSINUSITIS:  
 Contrary to the prevailing belief that fungi were responsible for CRS in 
only a selected group of patients with distinct pathophysiology, Ponikau et al in 
1999 demonstrated the presence of fungi in nasal mucus from 96% of patients 
with CRS and found type I hypersensitivity to be present in < 25% of their 
study group. They detected fungi along with eosinophil and eosinophil 
degraded products in mucus.5,96 They coined the term ‘eosinophilic fungal 
rhinosinusitis’ (EFRS)14. Similar results were observed by Braun et al 97and 
Polzehl et al98. 
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iii. EOSINOPHIL MUCIN RHINOSINUSITIS: 
 Ferguson et al described the presence of eosinophilic mucin without the 
presence of fungi in a proportion of rhinosinusitis patients and named this 
entity eosinophilic mucin rhinosinusitis (EMRS)15 and suggested that EMRS is 
a systemic disease with dysregulation of immunological control. In the analysis 
of pathophysiology of eosinophil related FRS, it has been suggested that fungal  
elements trapped in the mucus in sinuses are the source of antigenic material 
that stimulates IgE, IgG and IgA production.16 
 Various authors propose fungal rhinosinusitis to be a continuous 
spectrum of disease starting from the noninvasive to the acute invasive 
varieties with considerable overlap and transition from one form to another in 
the same patient.  Rowe-Jones and Moore-Gillon in 1994 proposed chronic 
destructive but noninvasive (semi invasive)form of fungal rhinosinusitis.17 It is 
categorized by sinus expansion and bone erosion, but with no histologic 
evidence of tissue invasion. In this state, the pathogens lead to progressive 
chronic inflammation intermediate between allergic sinus fungal ball, and 
chronic invasive state. 
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Categories of fungal rhinosinusitis6 
Category Host immune status Role of fungus
Major fungus 
isolated Course 
Invasive    
 
 
 
1.Granulomatous 
invasive 
Immuno 
Competent 
Pathogen  A. Flavus 
 
Indolent, 
chronic 
2.Chronic invasive  
 
Often diabetes 
mellitus, steroid 
therapy 
Pathogen  
 
A. fumigatus Chronic 
3.Acute invasive 
(fulminant 
necrotizing) 
Immuno 
Compromised 
Pathogen  
 
 
Zygomycetes 
Aspergillus spp. 
Acute 
Noninvasive      
1.Localized 
colonization 
(Saprobic 
infestation) 
Immuno 
competent 
Saprobe Aspergillus spp. May or 
may not 
progress to 
other 
forms 
especially 
sinus 
fungal ball 
2 Fungal ball 
(Mycetoma/Asper
gilloma) 
Immuno 
competent 
Saprobe Aspergillus spp. Chronic 
3.Eosinophil 
related 
    
AFRS Atopic  Allergen Dematiaceous 
fungi,A.flavus 
Chronic 
EFRS Majority atopic Activation of 
eoinophil 
Dematiaceous 
fungi 
Chronic 
EMRS Asthma,aspirin 
sensitivity,IgG1 
deficiency 
Unknown Not present Chronic 
         
AFRS = Allergic fungal rhinosinusitis; EFRS = Eosinophilic fungal                     
rhinosinusitis; EMRS = Eosinophilic mucin rhinosinusitis   
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EPIDEMIOLOGY OF FUNGAL RHINOSINUSITIS: 
HOST FACTORS:  
 Inhalation of ubiquitous fungi like Aspergillus and Zygomycetes is an 
innocuous phenomenon. However, in the immunodeficient host, these fungi 
may breach host defenses and propagate within and along the blood vessels and 
nerves, infecting sinonasal tissue and creating an acidotic area of tissue 
necrosis that is ideal for continued fungal proliferation.6 Widespread use of 
steroid is also an important cause of increased incidence of the disease.26,28,29 
The steroid acts by two ways – suppressing normal inflammatory cell response 
and by inducing a diabetic stage. Other risk factors found to be associated with 
development of  invasive fungal rhinosinusitis include long-term antibiotic 
usage, indwelling catheters, nasal intubations, metabolic abnormalities, 
prolonged hospitalization, and sinus disease For AFRS, atopy defines the 
condition and persons with type I hypersensitivity to fungi are exclusively 
affected by the disease92,93. AFRS is also found more in persons with simple 
asthma and aspirin sensitive asthma.94 However, prior sinus surgery seems to 
be a more important risk factor for development of  sinus fungal ball95. It has 
been speculated that sinus fungal ball may develop in any poorly ventilated 
sinus and that fungal exposure and poor sinus ventilation may be the only risk 
factors that are required.12In a case-control study, endodontic treatment on 
maxillary teeth was found to be a strong risk factor for fungal ball of  the 
maxillary sinus.20 
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Agent Factors: 
 Zygomycetes are by far the commonest cause of acute invasive fungal 
rhinosinusitis. The predominant Zygomycetes causing such disease is Rhizopus 
oryzae.28,32 The most common septate fungi causing acute invasive FRS in the 
immunocompromised patient are Aspergillus  fumigatus and Aspergillus  flavus 
.In contrast to foreign literature,  in the Indian scenario A. flavus is isolated in 
more than 80% of cases of AFRS, both in southern and northern parts of the 
country6,22. In granulomatous invasive FRS A. flavus is the commonest 
pathogen isolated. In contrast A. fumigatus causes most cases of chronic 
invasive FRS. Only 30 to 50% of the cultures  from fungal ball show the 
growth of the causative fungi, which are usually Aspergillus fumigatus or 
Aspergillus flavus and occasionally P. boydii100. 
PATHOGENESIS: 
 Inhalation of ubiquitous fungi like Aspergillus and Zygomycetes is an 
innocuous phenomenon. However, in the immunodeficient host, these fungi 
may breach host defenses and propagate within and along the blood vessels and 
nerves, infecting sinonasal tissue and creating an acidotic area of tissue 
necrosis that is ideal for continued fungal proliferation.6 Widespread use of 
steroid is also an important cause of increased incidence of the disease.26,28,29 
The steroid acts by two ways – suppressing normal inflammatory cell response 
and by inducing a diabetic stage. Other risk factors found to be associated with 
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development of invasive fungal rhinosinusitis include long-term antibiotic 
usage, indwelling catheters, nasal intubations, metabolic abnormalities, 
prolonged hospitalization, and sinus disease. Conidia of aspergilla are often 
present in ambient air, but large amounts of them are present in dust, 
decomposing organic matter and soil. So, inhalation is the most common route 
of entry of the fungi into the sinus .The pathogenesis of  mucormycosis is 
unclear and although the source is undoubtedly exogenous, possible sources 
have only been occasionally suggested. e.g adhesive dressings and air 
conditioning filtering units25. 
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 The fungi causing different categories of fungal rhinosinusitis are as 
follows. 6 
Category of fungal 
rhinosinusitis 
Commonly isolated 
fungus 
Rarely isolated fungus 
 
Granulomatous 
invasive FRS 
A. flavus 
 
 
Chronic invasive FRS A. fumigatus, less 
commonly A. flavus 
Mucor, Alternaria 
alternata, Candida, 
Drechslera, Bipolaris 
hawaiiensis,Sporothrix 
schenckii, Pseudallescheria 
boydii,  
Exserohilum spp, Fusarium 
spp 
Localized colonization Aspergillus fumigatus, 
other Aspergillus spp. 
Alternaria alternata, 
Penicillium rugulosum, 
mycelia sterilia, 
mucoraceous fungi. 
Fungal ball 
(Mycetoma/ 
Aspergilloma) 
Aspergillus fumigatus, 
Aspergillus flavus and 
occasionally P. boydii. 
Chaetomium globosum, 
Scedosporium prolificans, 
Aspergillus nidulans, 
Penicillium 
spp.Schizophyllum 
commune, very rarely 
zygomycetes. 
 
AFRS 
Dematiaceous fungi in 
USA  
Alternaria alternata, 
Bipolaris spp., 
Drechslera spp 
Curvularia lunata, 
Exserohilum. 
Aspergillus flavus in 
India and Middle East.
Schizophyllum 
commune,Aspergillus 
nidulans, Epicoccum 
nigrum,Penicillium sp. and 
Cladosporium spp. 
 
 
 
Eosinop
hil 
related 
FRS  
 
EFRS Similar to AFRS  
 
AFRS = Allergic fungal rhinosinusitis; EFRS = Eosinophilic fungal 
rhinosinusitis; EMRS = Eosinophilic mucin rhinosinusitis 
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PATHOGENESIS: 
Signs and symptoms seen with fungal infections are as follows21,22 
1. Nasal obstruction                             2. Rhinorrhoea 
3. Olfactory disturbance                      4. Facial pain /headache 
5. Facial fullness                                   6.  Anosmia/ hyposmia 
7. Proptosis                                           8. Visual impairment 
9. Focal neurological deficits                10. Seizures 
11. Altered sensorium                           12.  Purulence in nasal cavity  
13. Halitosis                                           14. Fatigue/dental pain 
INVESTIGATIONS: 
 A battery of investigations are done for all the cases of CFRS.they 
include21 
 Total count, differential count,absolute eosinophil count for 
diagnosing allergic fungal sinusitis. 
 Total serum IgE ,Blood sugar levels. 
 Liver function tests,HIV testing . 
 Anergy panel for cellular and humoral immunity. 
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PLAIN RADIOGRAPHY: 
 May show mucoperiosteal thickening with homogenous and complete 
sinus opacification. Radiologic evidence of sinusitis of one or more paranasal 
sinuses with or without flocculent calcifications is supportive of  allergic 
FRS21. 
COMPUTED TOMOGRAPHY:  
 It is the imaging study of choice .It shows typically a rim of soft tissue 
attenuation along the bony walls of the involved sinus that is completely or 
almost completely opacified in fungal ball. Allergic fungal sinusitis may show 
bony erosion or deformity. A typical feature is the presence of hyperdensity 
amid soft tissue opacity of the sinus lumen.6Chronic invasive fungal disease 
typically demonstrates significant soft tissue thickening and evidence of altered 
adjacent bone58. 
MAGNETIC RESONANCE IMAGING: 
 MRI is recommended for impending invasion into the orbit and 
intracranial compartment. In AFS, MRI will typically reveal mild to moderate 
signal intensity on T1 weighted images with loss of  signal intensity with T2 
weighted images21. 
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CHEST XRAY: 
 It should be considered in patients with allergic fungal sinusitis and 
pulmonary symptoms. 
DIAGNOSTIC NASAL ENDOSCOPY: 
         Findings may include:21 
 Fungal tufts –growing on retained secretions 
 Polypoidal swellings /polyps 
 Allergic mucin may be seen in cases of allergic fungal  
sinusitis.(golden yellow peanut butter like) 
 Soft cheese like material(white to brown/black) 
 Brown concretions ,Granulomatous mass 
 White necrotic debris ;Black mucosal eschar 
HISTOPATHOLOGY: 
 Histopathological appearance of lesions is an usual adjunct in 
establishing the diagnosis, prognosis and for deciding treatment protocols55,8 
1) GRANULOMATOUS INVASIVE FRS: 
 Histopathologically, Noncaseating granuloma with foreign body or 
Langhans’type of giant cells may be seen, sometimes with vasculitis, vascular 
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proliferation and  perivascular fibrosis. Hyphae in many occasions are scanty 
and are present inside the giant cells.7,52 
2) CHRONIC INVASIVE FRS: 
 In contrast to Granulomatous invasive FRS, the entity is characterized as 
dense accumulation of hyphae, occasional presence of vascular invasion, sparse 
inflammatory reaction, and involvement of local  structures.7,52,87 
3) FUNGAL BALL: 
 The fungal ball is diagnosed microscopically by the marked absence of 
significant inflammatory cell infiltrate and abundance of tightly packed fungal 
hyphae. Surrrounding mucosa demonstrates chronic inflammatory infiltrate 
with mild to moderate plasma cell and lymphocyte infiltrate.90,91 
4) ALLERGIC FUNGAL SINUSITIS: 
 The features are Scattered fungal hyphae in mucinous material with 
abundant eosinophils and Charcot leyden crystals. Allergic mucin is 
characterized by clumps of eosinophil and other cellular debris, within a 
background of pale eosinophilic -basophilic, amorphous mucin. The fungal 
elements tend to be sparse and are without subepithelial tissue invasion or 
fungal ball format55. 
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SPECIMEN COLLECTION AND PROCESSING: 
 The collection, transport and processing of clinical specimens 
encompass one of the most important considerations in determining the 
etiology of fungal disease. 
IDEAL SAMPLE: 
 Surgical samples should be transported in a sterile container .A few 
drops of  sterile saline may be added to keep the  sample moist. Fungal viability 
may be affected by excessive heat or cold. So room temperature transport and 
storage ideally within 2 hours is recommended.23,3 
DIRECT EXAMINATION : 
 Hyphal elements and details of hyphal morphology of aspergilli   can  be 
readily observed in routine  10 % Potassium hydroxide preparations without or 
with a fluorescent compound such as Calcoflour white or in tissue sections by 
fungal stains such as Gomori methenamine silver staining23. 
 As mucorales are common lab contaminants, microscopic demonstration 
of the presence of mucorales in clinical material taken from necrotic lesions is 
more significant than isolation of the same in culture. In contrast to aspergillus, 
Zygomycetes are larger, do not have parallel walls with 45 0 angle branching, 
and do not radiate from a single point in tissue. Furthermore, mucorales stain 
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poorly by Periodic acid-schiff stain but stain well with H & E stain and Gomori 
stain. Another stain that is useful is Cresyl Fast Violet which stains the 
Zygomycete wall brick red and other fungi blue or purple.23 
ANTIGEN DETECTION:  
 In patients with invasive disease, antigen detection may be very useful. 
Several tests for detection of soluble antigens of Aspergillus  spp in serum, 
urine or other body fluids have been developed. Radio immunoassay, Enzyme 
linked immune sorbent assay,Biotin avidin linked immunosorbent assay, Latex  
agglutination and Immunoblotting have been the most commonly used method, 
but only a few of them are commercially available.e.g a latex agglutination test, 
Pastorex Aspergillus and a ELISA Platelia Aspergillus are available. 
Regardless of the test used ,success of detecting antigenemia is directly related 
to the frequency of monitoring of samples,The Platelia ELISA detected antigen 
before diagnosis was made by other means in approximately two third of the 
patients 23,1.These tests identified the Aspergillus Galactomannan.  
Limitations:23 
 Use of antifungals significantly reduces the sensitivity of the assay. 
 ELISA reactivity noted with treatment with β lactam antibiotics(may 
be because  Penicillium species are used for drug production) 
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 False positive with beta glucan occur in patients with renal failure  
undergoing dialysis with cellulose membranes and those treated on  
immunoglobulin products. 
 There are no routinely available antigen detection formats for the 
diagnosis of Mucormycosis and agents of other hyalohyphomycosis. Tests that 
detect(1-3)β –D-Glucan,a characteristic cell wall component of a broad range 
of fungal pathogens has also been developed but clinical experience is limited. 
β –D-Glucan is detected by a glucan assay on the basis of its recognition by the 
immune system of Horseshoe crab ,specifically Tachypleus tridentatus and 
Limulus polyphemus . Factor G is activated by the glucan .The Limulus lysate  
assay and BG specific variant Fungitell assay has been approved for use.This 
assay is manufactured  by removing bacterial endotoxin sensitive factor C from 
limulus lysate making this reagent specific for beta glucan. This modified 
lysate is formulated with a synthetic chromogenic substrate and salts. The 
sensitivity and specificity are 69.9% and 87.1% respectively.24 
NUCLEIC ACID DETECTION TECHN IQUES: 
 Though highly sensitive and specific , they are still in experimental 
stage. Different approaches have been tried to detect a broad range of fungi in 
the first step and to identify to species level in the second step. Further, 
technical advances in post amplification analysis have enabled real time 
detection and quantification of fungal DNA load in tissue or blood samples.1 
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TYPING SYSTEMS: 
 It is done mainly for epidemiological studies. Restriction fragment 
length polymorphism analysis, Random amplified polymorphic DNA analysis 
and repetitive element and /or complex probes with southern blotting are the 
methods available. Genotyping has suggested that aspergillosis has a 
nosocomial origin in some cases23. 
ANTIFUNGAL SUSCEPTIBILITY TESTING: CLSI M 38 A 
DOCUMENT FOR MICROBROTH DILUTION OF FILAMENTOUS 
FUNGI:34 
 This document is the reference method of susceptibility testing of  
filamentous fungi. This provides a standard basis from which other methods 
can be developed.34 
Suitable for Conidium-and spore 
forming fungi 
Inoculum 0.4x104-5x104 CFU/ml 
Inoculum  Standardization Spectrophotometrically 
Test medium RPMI 1640 
Format Microdilution 
Temperature 35°C 
Duration of incubation 24 h/48h 
Endpoint No visible growth 
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AGAR DILUTION: 
 Agar dilution method  has been done in yeast nitrogen base agar with 
good reproducibility51 
E TEST: 
 Etest is a commercially available method and directly quantifies 
antifungal susceptibility in terms of discrete MIC values. For Aspergillus spp., 
good correlations with Amphotericin B and Itraconazole Etest and M38-A 
method have been demonstrated. Etest was superior in detecting caspofungin 
resistance in A. fumigatus, when compared with EUCAST and CLSI 
methodology. 37,39 
DISK DIFFUSION: 
 Disk diffusion interpretive criteria are available by the latest CLSI 
document.Espinel –Ingroff et al in a multicenteric evaluation, have studied the 
disk diffusion assay  for filamentous fungi45  and concluded that the optimal 
conditions were (i)plain Mueller Hinton agar,(ii) incubation times of 16-24 
hours for zygomycetes, 24 hours for Aspergillus  fumigatus,A.flavus, A.niger 
and 48 hours for other species and (iii) Itraconazole, Amphotericin10µg, 
Posaconazole 5µg, Voriconazole 1 µg, Caspofungin 5 µg disks. 
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 Sensititre® YeastOne™ Test Panel . This is a microtitre broth dilution 
method based on the CLSI M27-A2 standard described above. Each test 
consists of a disposable microtitre plate, which contains dried serial dilutions of 
six antifungal agents, Amphotericin B (range 0.008-16 µg/ml), Fluconazole 
(range 0.125-256 µg/ml), Itraconazole (range 0.008-16µ g/ml), Ketoconazole 
(range 0.008-16 µg/ml) and 5-Flucytosine (range 0.03-64 µg/ml), Voriconazole 
(range 0.008-16 µg/ml) in individual wells . The wells also contain Alamar 
Blue as a colorimetric indicator, which greatly improves the end point 
readability by a colour change from blue to pink. Results are expressed as an 
MIC and comparative studies against the CLSI method have shown favorable 
results 48. Excellent shelf life and the test also works with moulds, especially 
those that sporulate freely like Aspergillus40,41. 
 Neo-Sensitab: 
 This is a simple agar diffusion method using tablets to determine the 
susceptibility of fungi to antifungal agents. Once again there have been 
problems with which media to use and with the interpretation of the end points. 
Recent studies have used Mueller-Hinton agar supplemented with 2% glucose 
and 0.5 mcg/ml methylene blue as the medium49 ( CLSI M44-P method ) and a 
Biomic plate reader to electronically read and interpret zones sizes. However, 
individual disk zone sizes are often not able to differentiate between 
Susceptible and Susceptible Dose Dependent isolates and the correlation 
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between zone size and MIC is more variable48. Once again, resistant isolates 
need to be confirmed by using one of the appropriate CLSI methods. 
TREATMENT: 
NON INVASIVE FUNGAL SINUSITIS: 
1.SUPERFICIAL MYCOSIS/FUNGAL BALL: 
 
 Treatment includes mainly debridement of involved sinus. Antifungal 
agents are not used. Culture directed antibiotics to combat co existent bacterial 
infection may be used. 
2. ALLERGIC FUNGAL SINUSITIS: 
 Allergic fungal sinusitis is best managed with an aggressive 
combination of medical and surgical therapy. Complete surgical drainage with 
restoration of sinus aeration and mucociliary clearance is a corner stone of 
therapy, but it is alone insufficient to manage the condition. Medical 
management includes culture directed antibiotics, mucolytic therapy, 
antihistamines, systemic steroids, immunotherapy and /or anti fungal 
chemotherapy. Itraconazole has been used for allergic fungal sinusitis in 
conjunction with an initial burst of systemic steroids.21 
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INVASIVE FUNGAL SINUSITIS: 
1. CHRONIC INVASIVE FUNGAL SINUSITIS: 
 This condition is best handled by a combination of medical and surgical 
treatments. Wide local resection is preferred in combination with appropriate 
antifungal therapy. 21 
2. ACUTE INVASIVE FUNGAL SINUSITIS:  
 Debridement of all grossly infected and devitalized tissue is mandatory. 
Orbital exenteration in patients with known cerebral involvement and very poor 
vision may help reduce the burden of infected tissue. Wound packing that is 
impregnated with Amphotericin can be used. Following surgery, irrigation of 
nasal cavity with Amphotericin B(50 mg /L of water)irrigations(20 ml 4 times 
a day) may be performed. Other therapies that have been tried include 
hyperbaric oxygen and G-colony stimulating factor infusion. Despite 
aggressive therapy and surgical debridement, the mortality rate is very high. 
Overall survival in diabetic patients approaches 80 % when underlying ketosis 
is corrected.21 
ANTIFUNGAL THERAPY: 
 Therapy is indicated only for mold infections of the sinuses .Candida 
spp are not implicated as a cause of fungal sinusitis though asymptomatic 
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colonization of sinuses are often present ,hence antifungal chemotherapy is not 
usually advocated against them. 
Clinically useful antifungals available for moulds: 
 Polyenes: Amphotericin B,Amphotericin B lipid formulation 
   Azoles:  Itraconazole,Voriconazole,Posaconazole 
 Echinocandins:   Caspofungin,Micafungin,Anidulafungin 
AMPHOTERICIN B: 
 Mechanism of action: It binds to ergosterol in fungal cytoplasmic  
membrane, increasing permeability and causing leakage of intracellular 
components. Membrane channel activity is increased at lower doses and pores 
are formed at higher doses52 
 Spectrum of activity:  Good activity against most Candida species, 
Aspergillus spp, Cryptococcus spp. and dimorphic moulds.  Dosage:0.7 to 1.5 
mg/kg/day 
LIPID FORMULATIONS OF AMPHOTERICIN B: 
Three formulations available: 
 Amphotericin B colloidal dispersion 
 Amphotericin B lipid complex 
 Liposomal amphotericin B 
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FDA indications: 
 Fungal infections intolerant/refractory to amphotericin 
 Empirical therapy in febrile neutropenics 
Dosage: 3-6 mg/kg/dose iv. 
AZOLES52,24: 
ORGANISM ITRACONAZOLE VORICONAZOLE POSACONAZOLE 
A.fumigatus + ++ ++ 
A.flavus ++ ++ ++ 
A.terreus ++ + ++ 
Fusarium - -/+ -/+ 
Rhizopus spp -/+ - + 
Mucor spp -/+ - - 
Scedosporium 
apiospermum 
+ +/++ +/++ 
S.prolificans - -/+ - 
Dematiaceous 
fungi 
+/++ +/++ +/++ 
 
 
 
 
36
Mechanism of action: 
 Inhibition of cytochrome P-450- dependent lanosterol 14-demethylase, 
an enzyme required for the synthesis of ergosterol,  the main component of 
fungal cell membranes. This results in the accumulation of methylated sterols , 
depletion of ergosterol and inhibition of cell growth.52 
Dosage: 
Itraconazole: 200 mg b.i.d 
Voriconazole 6 mg/kg q12 h IV OR 200 mg q12 h 
Posaconazole 100 mg b.i.d 
Indications: 
 Itraconazole: Invasive aspergillosis refractory to amphotericin.  
 Voriconazole: Approved as primary therapy in invasive aspergillosis. 
 Posaconazole: Prophylaxis of invasive fungal infections. 
 Shown to have good activity against zygomycetes. 
 
 
 
37
ECHINOCANDINS:24 
MECHANISM OF ACTION: 
 Mechanism of action is noncompetitive inhibition of enzyme glucan 
synthase which produces (1,3)β d glucan. The destruction of cell wall structure 
leads to osmotic instability and ultimately lysis of  the fungal cell52. 
 Caspofungin : 70 mg iv loading dose followed by a daily 50 mg IV 
dose52. 
INDICATIONS: 
             It is indicated in the treatment of invasive aspergillosis in patients who 
are refractory to or intolerant of other antifungals.It is also approved as 
empirical therapy for presumed fungal infections in neutropenic patients. 
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MATERIALS AND METHODS 
PLACE OF STUDY: 
 This cross sectional study was conducted in the Institute of 
Microbiology, Madras Medical College in association with Upgraded Institute 
of Otorhinolaryngology, Rajiv Gandhi Government General Hospital, Chennai. 
All patients undergoing functional endoscopic sinus surgery (FESS) and/or 
diagnostic nasal endoscopy (DNE) were both taken under the study. 
STUDY PERIOD: 
 The study period was from January 2010 to June 2011.  
ETHICAL CONSIDERATION: 
 Approval was obtained from the Institutional Ethical Committee before 
the commencement of the study. Informed consent was obtained from the study 
population. All patients satisfying the inclusion criteria were documented. 
Patients were interviewed by structured questionnaire. 
STUDY POPULATION: 
 All consecutive   Patients >18 years of age within the study period with 
 Radiologically proven sinusitis with 
 Symptoms > 12 weeks duration 
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 whose DNE/ FESS sampling or clinical condition is suggestive of  
fungal involvement in the pathogenesis of the disease were included in 
the study. 
EXCLUSION CRITERIA: 
 Patients with symptoms of sinusitis < 12 weeks duration  and age<18 
years were excluded from the study. 
DATA COLLECTION : 
 Data collection included name, age, sex, address, date of admission, 
diagnosis at admission, physical examination findings and Demographic profile 
which include H/O asthma, aspirin allergy, peripheral blood eosinophilia, 
Diabetes mellitus, Chronic eczema/dermatitis, COPD, Uremia/chronic kidney     
disease, neoplasm, immunosuppressive therapy, recurrence and injury /trauma 
to  the sinuses. 
STATISTICAL ANALYSIS: 
 Statistical analysis were carried out using Statistical Package for Social 
Sciences (SPSS) and Epi-Info softwares by a statistician. The proportional data 
of this cross sectional study were tested using Pearson’s Chi Square analysis 
test and Fisher exact probability test . 
 
 
 
40
CASE DEFINITIONS: 
INVASIVE FUNGAL INFECTIONS: 
 Diagnostic criteria for invasive fungal infections as defined by 
deShazo:9 
 Mucosal thickening or air fluid level compatible with sinusitis on  
radiography. 
 Histopathological evidence of hyphal forms within the sinus mucosa , 
submucosa,blood vessel or bone. 
 To diagnose GRANULOMATOUS INVASIVE SINUSITIS, 
histopathological evidence of hyphal forms within the sinus mucosa 
,submucosa, bloodvessel or bone in association with granuloma containing 
giant cells. 
FUNGAL BALL:  
 Diagnostic criteria for fungal ball as defined by deShazo12 
 Radiological studies showing sinus opacification often associated with  
floccular calcifications. 
 Mucopurulent cheesy clay like material presenting at a single sinus at  
time. 
 Histopathological evaluation showing dense agglomeration of  hyphae 
separate from adjacent respiratory mucosa and absence of allergic 
mucin. 
 No fungal invasion of tissue or mucosa. 
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ALLERGIC FUNGAL RHINOSINUSITIS(AFRS): 
 Patients with a combination of the following findings were diagnosed as 
having. AFRS as per diagnostic criteria described by Bent and Kuhn:4 
 Radiologically proven sinusitis. 
 Presence of allergic mucin within nasal cavity or sinuses. 
 Demonstration of fungal hyphae in allergic mucin. 
 Absence of fungal invasion in histopathology 
 Absence of  diabetes, immunodeficiency or recent treatment with 
Immunosuppressants 
 Invasive fungal infections are defined in terms of “PROVEN”, 
“POSSIBLE”; “PROBABLE”35. 
PROVEN: 
 POSITIVE culture obtained by a sterile procedure from a 
normally sterile site and clinically and radiologically abnormal 
site consistent with infection 
PROBABLE: 
 Atleast one criteria from host section ,one microbiological criteria 
and one major or two minor clinical criteria from an abnormal 
site consistent with infection. 
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POSSIBLE: 
 Atleast one criteria from host section and one microbiological or 
one major (or two minor) clinical criteria from an abnormal site 
consistent with infection. 
CRITERIA: 
Host factors: 
 Neutropenia(>500/mm3 for >10 days) or coexistent AIDS. 
 Persistent fever >96 hours refractory to antibiotics 
 Body temperature> 38oC or <36oC 
 Recent or current use of immunosuppressive agents or steroids>3 
weeks 
Microbiological criteria: 
 Positive result of culture or findings of cytological /direct 
microscopic evaluation for mould  from sinus aspirate sample 
Major: 
 Suggestive radiological evidence of invasive infection in 
sinuses(involvement of sinus walls, neighbouring structures and skull 
base) 
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Minor: 
 Upper respiratory tract infections 
 Nose ulceration or eschar 
 Periorbital swelling 
 Maxillary tenderness 
 Perforation of hard palate 
SAMPLE COLLECTION: 
 Sample collection was done according to American Thoracic Society 
Recommendations for collection of specimen for fungal culture.31 
 Tissue biopsies or endoscopic aspirates were transported immediately in 
a sterile gauze moistened with physiologic, sterile saline solution in a screw 
capped sterile container. Care was taken so that the specimen was not frozen or 
allowed to dehydrate before culture. 
CRITERIA FOR REJECTION: 
 Improperly labelled samples  
 Samples that are transported in unsterile containers 
 Samples that have leaked or show signs of dehydration 
 Samples received in formalin31 
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 As the sample is collected, the endoscopic grading of AFS46 as described 
by  Kupferberg et al is also noted if applicable(for AFRS): 
 GRADE      0:   No evidence of disease 
 GRADE    1:   Edematous mucosa+allergic mucin 
           GRADE     2:    Polyps+allergic mucin 
           GRADE     3:    Polyps and fungal debris 
PROCESSING OF SPECIMENS: 
 When processing tissue for the recovery of fungi, the use of a mortar or 
tissue grinder was avoided31,33. The tissue was minced into 1 mm cubes with a 
sterile scissors or a sharp scalpel blade and the tiny fragments were placed 
directly on the agar. Sabouraud Dextrose Agar was used for primary isolation.31 
DIRECT EXAMINATION: 
POTASSIUM HYDROXIDE (KOH)MOUNT PREPARATION:31,33 
 A clean, grease free glass slide was taken. One large drop of 10% KOH 
solution was placed on the slide. A small quantity of the specimen was mixed 
in the KOH drop. A clean coverslip was placed over the drop. The slide was 
placed in a moist chamber at room temperature. Tissue usually takes 20-30 
minutes to clear. It is observed under low and high power for the presence of 
yeasts or hyphal forms. Simultaneously the specimen was also processed in 
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Institute of Pathology, Rajiv Gandhi Government General hospital. 
Haematoxylin and Eosin stain was done routinely. Special stains like Giemsa, 
Periodic acid Schiff and Gomori Methenamine silver staining were also done in 
case of suspicious fungal forms in H &E stain. 
CULTURE: 
 A minimum of 5 ml31 of tissue homogenate was inoculated onto 2 slants 
of Sabouraud Dextrose Agar with antibiotics Gentamicin added at a 
concentration of 20mg/litre32. Inoculated tubes were incubated at 25 and 37 O 
C. Cultures were examined for expected growth, daily in the first week and 
twice a week for the subsequent period. Cultures were incubated for a 
minimum of 4 weeks and in some cases upto six weeks before being discarded 
as sterile.32 
INTERPRETATION OF FUNGAL CULTURES: 
 The following features were considered before labelling an opportunistic 
fungi that are otherwise considered as contaminants as pathogen:32 
 Isolation of same strain in all culture tubes 
 Repeated isolation of same  strain in multiple specimens 
 Immune status of the patient 
 Direct microscopic detection of fungal forms 
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DENTIFICATION OF FUNGAL ISOLATES: 
 All isolates were systematically identified by standard techniques. 
               Various mounting methods done include 
1) Tease mount 
2) Scotch tape 
3) Slide culture technique 
1) Tease mount: 
 A small drop of lactophenol cotton blue (LPCB) was placed on a clean 
microscopic slide. A small portion of growth was removed midway between 
the colony center and edge. The removed colony was placed on a drop of 
lactophenol cotton blue on the slide. The growth was teased using a pair of 
dissecting needles so as to have a thin spread out. The coverslip is placed 
gently at the edge of the drop of mounting fluid avoiding trapping of air 
bubbles.32,33 
2)  Scotch tape technique: 
 A drop of mounting fluid was placed on the slide.A 2 cm long tape was 
taken and one end was touched to a forceps /stick and the other end to the 
colony. The tape with the surface containing fungus was laid face down into  
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the mounting medium on the slide.The tape was detached from the stick and 
mount  examined 32 
3) Slide culture technique:  Setup: In a 100 mm glass petri dish, a filter paper, 
V-shaped glass rod, a slide and a coverslip  placed . The whole setup is 
autoclaved at 1210C for 15 minutes at 15 pounds33. 
Procedure: 
 1 cm square agar was cut aseptically from potato dextrose agar. The agar 
block was transferred to the slide in the setup. A very small amount of the 
colony was transferred to the four sides of the agar block. A coverslip was 
placed on the inoculated agar block.1-1.5 ml of sterile water was added to the 
filter paper. 5%glycerin was added to the sterile water to prevent condensation 
of moisture on the slide. Slide culture was incubated in the dark at room 
temperature till good sporulation occurs. 
Removing the  slide culture: 
 A small drop of mounting fluid was placed on a slide.With forceps,the 
cover slip was carefully removed.A drop of 95 % alcohol was added to the 
cover slip to wet the colony and to prevent trapping of air bubble. The cover 
slip was placed carefully on the mounting medium. The excess of mounting 
fluid was removed and the mount was examined under microscope.33 
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 MOULD IDENTIFICATION SCHEME 33 
This includes    
 Growth rate 
 Colony characteristics; 
 Texture ,Colour(obverse ,reverse) 
 Microscopy: 
i. Fruiting structures: Synnemata, Pycnidia,  
Ascocarps(Gymnothecia,Cleistothecia,Perithecia) 
ii. Hyphae: Colour, Size, Septation, Special Structures 
iii. Conidiogenesis: Conidiogenous cell,Proliferation of conidiophore 
. 
ANTIFUNGAL SUSCEPTIBILTY TESTING:33,32,31,34 
 Amphotericin B and Itraconazole powders were obtained from HiMedia, 
Mumbai and Pharma Fabricon respectively. Their assay potency were 750 
µg/mg each. 
Weight (mg) =volume (ml)x  desired concentration (µg/ml) 
                           Assay potency (µg/ml) 
Volume(ml)=weight (mg)x assay potency(µg/ml)  
                                  concentration (µg/ml) 
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STOCK SOLUTION: 
 Solvent used is Dimethyl sulfoxide(DMSO) for Amphotericin B and 
Itraconazole. Stock solution of 1600 µg/ml is prepared. A series of dilutions at 
100 times the final concentration was prepared from the antifungal stock 
solution in the same solvent. Each intermediate solution was then further 
diluted to final strength in the test medium. This procedure was done to avoid 
dilution artifacts that result from precipitation of compounds with low 
solubility in aqueous media. 
Media : RPMI 1640(with glutamine, without bicarbonate,and phenol red as pH 
indicator), HiMedia, Mumbai. 
Inoculum preparation: 
 All organisms were subcultured onto Potato dextrose agar , incubated at 
35oC for 7 days. The culture was covered with 1 ml of sterile 0.85% saline and 
a suspension prepared by gently probing the colonies. Addition of 1 drop of 
Tween 20 will help dispersion of Aspergillus conidia.The resulting mixture of 
conidia and hyphal elements was withdrawn and transferred to a sterile tube 
and allowed to settle. The uniform suspension was transferred to a screw 
capped tube and vortexed. The densities of the conidia or the sporangiospore 
suspensions were read and adjusted to a optical density of 0.09-0.11 for 
Aspergillus spp and 0.15-0.17 for Rhizopus spp by spectrophotometry. These 
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will be diluted 1:50 in the standard medium. This will give a  density needed of 
approximately 0.4x104 to 5x10 4 CFU/ml when mixed with the antifungal 
agent. 
INCUBATION: All microtitre plates were incubated at 35oC. Examination 
time for Rhizopus: 21-26 hours of incubation and Aspergillus spp: 46-50 hours 
of incubation. 
INTERPRETATION: 
 Minimum inhibitory concentration is the lowest concentration of an 
antifungal that substantially inhibits growth of the microorganism as detected 
visually. Each microdilution well was then given a numerical score as follows; 
Score    4   - No reduction of growth 
Score    3   - Slight reduction in growth(75 % of growth control) 
Score    2   - Prominent reduction in growth(50 % of growth control) 
Score    1   - Optically clear or absence of growth 
 One growth control well and one antifungal control well were also set 
up. Recommended MIC limits of reference strain ATCC A.flavus 204304 which 
was also put up as quality control.Amphotericin B : 0.5-4 µg/ml, Itraconazole: 
0.2-0.5µg/ml. 
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PROCEDURE: 
Starting 
conc 
1600 2 4 8 16 32 64 128 256 512 Rema
rks 
2x 4x 8x 2x 4x 8x 2x 4x 8x Tube(T) T1stoc
k 
T2 T3 T4 T 5 T6 T7 T8 T9 T10 
 
Add 
drug(ml) 
      + 
From 
T1 
    - 
From 
T1 
0.5 
+ 
From 
T1 
0.5 
+ 
From 
T1 
0.5 
+ 
From 
T4 
0.5 
+ 
From 
T4 
0.5 
+ 
From 
T4 
0.5 
+ 
From 
T7 
0.5 
+ 
From 
T7 
0.5 
+ 
From 
T7 
0.5 
+ 
Add DMSO 
(ml) 
   
 - 
 
0.5 
 
1.5 
 
3.5 
 
0.5 
 
1.5 
 
3.5 
 
0.5 
 
1.5 
 
3.5 
Step1 
 
 
 
 
Row 1 
Intermediate 
drug conc. 
 
1600 
 
800 
 
400 
 
200 
 
100 
 
50 
 
25 
 
12.5 
 
6.25 
 
3.313 
 
Add drug 
from row 
1above 
        
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
0.1 
+ 
 
RPMI 
(ml) 
 
4.9 
 
4.9 
 
4.9 
 
4.9 
 
 
 
4.9 
 
4.9 
 
4.9 
 
4.9 
 
4.9 
 
4.9 
Step 2 
Row 2 
(1:50) 
Final conc at 
1:50(µg/ml) 
 
32 
 
16 
 
8 
 
4 
 
2 
 
1 
 
0.5 
 
0.25 
 
0.125 
 
0.0625 
 
(2x) 
From row 2 
add drug to 
microtitre 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
Step 
3(1:1) 
Add 
inoculum to 
plate 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
 
0.1 
 
0.1 
 
0.1 
 
0.1 
 
Step 4 
Final drug 
conc. In well 
(µg/ml) 
 
16 
 
8 
 
4 
 
2 
 
1 
 
0.5 
 
0.25 
 
0.125 
 
0.0625 
 
0.0313 
 
 
CLINICAL SIGNIFICANCE: 
AMPHOTERICIN: MIC above 2 µg/ml have been associated with treatment  
failure and MIC below 2 µg/ml with clinical cure. 
ITRACONAZOLE: Preliminary data indicate that high Itraconazole MICs 
(MICs>8 µg/ml)are associated with clinical resistance to the drug.Data are not 
 
 
 
52
available to indicate a correlation between MIC and outcome of treatment with 
Itraconazole.  
DISC DIFFUSION METHOD AND E TEST: 
 Inoculum transmittance was adjusted according to CLSI M38-A 
protocol  as described above for microbroth dilution. Suspensions were applied 
to the surface of the agar media by using swab applicators;Mueller Hinton agar 
for disk diffusion45  and  RPMI agar for E test 44The inoculated plate was 
allowed to dry for 15 minutes .Amphotericin B 10µg and Itraconazole 10µg 
disks were applied on Mueller Hinton agar.44Estrip for Amphotericin B was 
applied onto the inoculated RPMI agar43.Zone diameters were measured in the 
disk diffusion assay to the nearest whole millimeter at the point where there 
was a prominent reduction of growth after 16-24 hours for zygomycetes and 
after 24,48 and 72 hours for the other species. E test was read after 24 hours  or 
when there was sufficient growth to take a reading.43,36,37,38.Zone diameter 
categories were44  
DRUGS SUSCEPTIBLE SUSCEPTIBLE 
DOSE 
DEPENDENT 
RESISTANT 
AMPHOTERICIN B ≥15 mm 13-14 mm ≤12 mm 
ITRACONAZOLE ≥17 mm 
 
14-16 mm ≤13 mm 
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AGAR DILUTION: 
 Stock solutions and Drug dilutions were prepared according to the CLSI 
M 38 A guidelines. For susceptibility testing, 1ml of Yeast nitrogen base was  
thoroughly mixed with 18ml of molten agar (Himedia, Mumbai) and 1 ml of 
corresponding drug dilution  and poured in 100mm sterile petri plates. Plates 
were dried prior to use. The inoculum concentration was adjusted to 1.0 X106 
cells per ml establishing 90% transmission at 530 nm by the method of 
Shadomy and Espinel-Ingroff 50. A 0.01-ml amount (1.0 x 104 spores) was 
delivered onto the surface of agar media in 100-cm2 petri dishes. A control 
SDA plate (20 ml of SDA) and a plate for each concentration of 0.125 to 16 
µg/ml serial dilutions were inoculated. Plates were incubated at 30°C for 48 h. 
The MIC was defined as the lowest concentration which caused greater than 
80% inhibition of growth compared with the growth on the control plate. This 
definition, rather than a 100% inhibition endpoint, eliminated films and proved 
reproducible results in preliminary experiments. 
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RESULTS 
  This study was conducted among a total of 380 cases of Chronic 
Rhinosinusitis who underwent Functional endoscopic sinus surgery and 
Diagnostic nasal endoscopy at the Upgraded Institute of Otorhinolaryngology 
during the study period. 80 cases which fulfilled the inclusion criteria were 
included in the study. Of the 80 cases, 43 cases were recognized as chronic 
fungal Rhinosinusitis  .Overall incidence of FRS was 11.3% in this study. 
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TABLE 1 
 
AGE AND SEX DISTRIBUTION OF PATIENTS WITH  
CFRS AND NFRS. 
 
 
CFRS(n=43) 
 
AFRS(n=29) FB(n=2) CGFRS(n=4) CIFRS(n=8) 
 
NON CFRS 
(n=37) 
 
 
Age 
distribution 
M 
 
F 
 
M F 
 
M 
 
F 
 
M 
 
F 
 
M 
 
F 
 
21-
30 
7 
(24%) 
6 
(21%) 
- - - - 1 
(12%) 
1 
(12. 
5%) 
4 
(11%) 
1 
(3%) 
31-
40 
- 
(0%) 
5 
(17%) 
 
- - 1 
(25%) 
- - 
(0%) 
- 
(0%) 
1 
(3%) 
5 
(14
%) 
Young 
adults 
Total 7 
(24%) 
11 
(38%) 
- - 1 
(25%) 
1 
(25%) 
1 
(12.5%) 
1 
(12. 
5%) 
5 
(14%) 
6 
(17
%) 
41-
50 
2 
(7%) 
2 
(7%) 
- 2 
(100   
%) 
1 
(25%) 
- 2 
(25%) 
1 
(12. 
5%) 
7 
(19%) 
7 
(19
%) 
51-
60 
2 
(7%) 
3 
(10%) 
- - 1 
(25%) 
- 1 
(12.5%) 
1 
(12. 
5%) 
3 
(8%) 
3 
(8%) 
Middle 
age 
Total 4 
(14%) 
5 
(17%) 
- 2 
(100
%) 
2 
(50%) 
- 3 
(38%) 
2 
(25%) 
10 
(27%) 
10 
(27
%) 
61-
70 
- 2 
(7%) 
- - - 
 
 
- - - 4 
(11%) 
1 
(3%) 
71-
80 
- - 
(0%) 
- - - 
 
 
- 1 
(12.5%) 
- - 
(0%) 
1 
(3%) 
>80 - - - - - 
 
 
- - - - - 
 
Old 
age 
Total - 2 
(7%) 
- - - - 1 
(12.5%) 
- 4 
(11%) 
 
2 
(5%) 
 
                          P =0.038      
  Of the total 43 cases of fungal sinusitis,22 (51% )were in the age group 
of 21-40(young adults). An almost equal number 18 patients (41.8%) were in 
the age group of 41-60(middle age) and a minor number (3) of patients in the 
age group>60(6.9%). In statistical analysis, p<0.05 was obtained. This is 
statistically significant. So, AFS predominated in the 21-40 age group (62%) 
whereas CIFRS predominated in 41-60 age group. P value for male /female 
association was 0.555 which is statistically insignificant. Therefore, gender 
does not make significant difference.                      
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TABLE 2 
             COMPARISON OF PRE OPERATIVE SYMPTOMS IN 
PATIENTS   WITH CFRS AND NON CFRS 
Symptoms NFRS(n=37) CFRS(n=43) 
Nasal block 26 
 
70 % 39 90.6% 
Nasal discharge 
 
33 89% 33 76.7% 
Headache 36 
 
97% 30 69.7% 
Facial puffiness - 
 
- 3 6.9% 
Proptosis - 
 
- 2 4.6% 
Anosmia/hyposmia 24 
 
65% 27 62.7% 
Tinnitus - 
 
- 1 2.3% 
RRTI # 24 
 
65% 36 83.7% 
Others* - 
 
- 5 11.6% 
 
#Recurrent respiratory tract infections                                                    (p=0.22) 
*Includes Diminished vision, altered sensorium, speech disturbances, nerve 
palsies. 
 Majority of patients of FRS presented with nasal block(90.6%) as the 
predominant complaint ,though Headache predominated as the presenting 
complaint(97%) in sinusitis of non fungal etiology,. Headache was the 
presenting complaint in only 69.7 % of the people with fungal sinusitis. 
Symptoms like proptosis, facial puffiness, tinnitus were more common in 
invasive fungal infections than in others. But this difference was not 
statistically significant. 
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TABLE 3 
           COMPARISON BETWEEN SITE OF INVOLVEMENT 
BETWEEN CFRS AND NON CFRS 
SITE INVOLVED CFRS  n (%) 
(n=43) 
Non CFRS (%) 
(n=37) 
PANSINUSITIS 25  (58%) 31  (84%)
Bilateral 6  (14%) 3  (8%)
R 2 (5%) 3  (8%)
Maxillary 
Sinus 
Unilateral 
L 4 (9%) - (0%)
Bilateral -  (0%) - (0%)
R - (0%) - (0%)
Frontal Sinus 
Unilateral  
L - (0%) - (0%)
Bilateral 3  7%) - (0%)
R - (0%) - (0%)
Ethmoid 
Sinus Unilateral 
L - (0%) - (0%)
Bilateral 3  (7%) - (0%)
R - (0%) - (0%)
Sphenoid Sinus 
Unilateral 
L - (0%) - (0%)
Orbit Involvement* 4 (9.3%) - (0%)
                                                                                                                      
 *observed along with other sinus involvement .      P=0.013
 Both Fungal and non fungal sinusitis involved all the sinuses in 58% and 
84% of cases .The next predominant was maxillary sinusitis that involved 24% 
of cases of CFRS and 16% of non CFRS. In statistical analysis, p<0.05 was 
obtained. So, it is a statistically significant fact that NFRS commonly presented 
as pansinusitis whereas FRS can affect even a single sinus.                                                           
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TABLE 4 
              CATEGORIZATION OF THE CASES OF FUNGAL   
SINUSITIS  n=43 
CATEGORIES MALE FEMALE TOTAL 
 
ALLERGIC FUNGAL 
RHINOSINUSITIS 
11 
(26%) 
18 
(42%) 
29 
(67%) 
FUNGAL BALL - 
(0%) 
2 
(5%) 
2 
(5%) 
CHRONIC FUNGAL 
GRANULOMATOUS 
SINUSITIS 
3 
(7%) 
1 
(2.3%) 
4 
(9%) 
PROVEN 4 
(9%) 
2 
(5%) 
6 
(14%) 
PROBABLE 1 
(2.3%) 
1 
(2.3%) 
2 
(5%) 
CHRONIC 
INVASIVE  
FUNGAL 
SINUSITIS 
POSSIBLE - - 
 
- 
                                             
 Allergic fungal sinusitis was the most common form of sinusitis that 
was noted. This contributed to 67 % of the cases. This was followed by 19 % of 
chronic invasive fungal sinusitis .There was no statistically difference in sex 
distribution of the cases. 
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TABLE 5 
COMPARISON BETWEEN RISK FACTORS ASSOCIATED WITH   
CHRONIC INVASIVE FUNGAL SINUSITIS AND OTHER 
CATEGORIES OF CFRS. 
OTHER CATEGORIES 
(AFRS, CGFRS, FB) 
(n=35) 
Risk Factors No. Of  
CIFRS 
(n=8) 
 AFRS 
(n=29) 
CGFRS
(n=4) 
FB 
(n=2) 
 
Total 
Hyperglycemia 6 
(75%) 
 
2 
(6.8%) 
- - 
 
 
2 
(6%) 
Chronic Kidney 
Disease 
1 
(12.5%) 
1 
(0.2%) 
- - 
 
 
1 
(0.2%
) 
Renal Transplant 1 
(12.5%) 
- - - 
 
 
- 
(0%) 
Asthma/Chronic 
eczema 
- 16 
(55%) 
- - 
 
 
16 
(46%) 
       
           None 
         1 
(12.5%) 
 
17 
(58.6%) 
4 
(100%) 
2 
(100
%) 
 
 
   23 
(66%) 
      
BY CHI SQUARE TEST: (P=0.002) 
 In statistical analysis, p<0.05 was obtained. So, it is a statistically 
significant fact that Hyperglycemia was a significant risk factor that favoured 
invasive forms of fungal sinusitis. Asthma was also a significant risk factor 
known in cases of AFRS. Comparison between presence of asthma in AFRS 
and other categories showed a P value of 0.002 which was statistically 
significant.Few patients had multiple risks.(diabetes+CKD,diabetes+asthma). 
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TABLE 6 
CORRELATION BETWEEN ENDOSCOPIC STAGING 45 AND 
RECURRENCE RATE OF ALLERGIC FUNGAL RHINO  
SINUSITIS, n=29 
Stage Description Number 
observed 
Percentage 
 
Recurrence % 
0 No evidence of 
disease 
- - 
 
- 0% 
I Edematous 
mucosa +allergic 
mucin 
 - 
 
- 0% 
II Polyps +allergic 
mucin 
      10      34.4%         4 13.7% 
III Polyps +fungal 
debris 
19 65.5% 11 37.9% 
 
 
 
 
 
 
 
P= 
0.599 
 
 A majority constituting 65.5 % of the allergic fungal sinusitis cases 
presented in a fairly advanced stage of the disease, i.e, stage III.61 % of 
recurrence was noted in stage III of the disease. The P value for the association 
between recurrence and stage of disease was 0.599.This association is 
statistically insignificant. 
TABLE 7 
 
COMPARISON BETWEEN DIRECT MICROSCOPIC OBSERVATION, 
HPE AND CULTURE EXAMINATION. 
Total number of cases 
 
43 Sensitivity  
 (%) 
Direct examination(10% 
KOH mount) 
 
41 
95.34 
Histopathology 
 
40 93 
 
 
Positive by 
Culture        38 
 
          88.37 
 
 Direct microscopy was able to clinch the diagnosis in 95.34 % of the 
cases, whereas Histopathology and Culture could do so in only 93% and                         
88.3% respectively. 
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TABLE 8 
ETIOLOGICAL FUNGAL AGENTS OF CHRONIC FUNGAL 
SINUSITIS AND THEIR RELATIVE FREQUENCY OF ISOLATION 
Species AFS 
(n=29) 
Fungal Ball 
(n=2) 
CGFRS 
(n=4) 
CIFRS 
(n=8) 
Total 
(n=43) 
A.flavus 16 
(55.1%) 
2 
(100%) 
1 
(25%) 
 
1 
(12.5%) 
20 
(46.5%) 
Rhizopus spp 1 
(3.4%) 
- 1 
(25%) 
 
4 
(50%) 
6 
(13.9%) 
A.fumigatus 3 
(10.3%) 
- 
 
1(25%) 1 
(12.5%) 
5 
(11.6%) 
A.niger 3 
(10.3%) 
 
- 
- - 3 
(6.9%) 
A.nidulans -  
- 
- 1 
(12.5%) 
1 
(2.3%) 
A.clavatus 1 
(3.4%) 
 
- 
- - 1 
(2.3%) 
A.versicolor 
 
- - 1 
(25%) 
- 1 
(2.3%) 
Penicillium spp. 1 
(3.4%) 
- - - 1 
(2.3%) 
Paecilomyces 
variotii 
1 
(3.4%) 
- - - 1 
(2.3%) 
 
KOH +/NG 
4 
(13.8%) 
- - 2 
(25%) 
6 
(13.9%) 
 
Mixed growth 1 
(3.4%)* 
- - 
 
1 
(12.5%)# 
2 
(4.6%) 
 
#A.fumigatus+Rhizopus spp       *A.niger+Rhizopus spp 
 
 Majority of the fungi isolated were Aspergillus spp. in particular A 
.flavus (46.5%). A. flavus was the commonest isolate in AFS(55%), Fungal 
ball(100%) and CGFRS. (25%).In CIFRS, however, Rhizopus spp were most 
commmonly isolated(50%). 
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TABLE 9 
MINIMUM INHIBITORY CONCENTRATION OF  
AMPHOTERICIN B TO DIFFERENT MOULDS BY BROTH 
DILUTION METHOD 
SPECIES NUMBER SENSITIVE 
(MIC<2µg/ml )* 
RESISTANT 
(MIC 
>2µg/ml) 
MEAN 
MIC 
(µg/ml) 
ATCC A.flavus 
204304 
1 1 
(100%) 
- 
 
0.5 
A.flavus 20 20 
(100%) 
- 
 
0.5 
Rhizopus spp 6 6 
(100%) 
- 
 
0.5 
A.fumigatus 5 5 
(100%) 
- 
 
0.25 
A.niger 3 3 
(100%) 
- 
 
0.125 
A.nidulans 1 1 
(100%) 
- 
 
1 
A.clavatus 1 1 
(100%) 
- 
 
1 
Penicillium spp. 1 1 
(100%) 
- 
 
0.5 
Paecilomyces 
variotii 
1 1 
(100%) 
- 
 
0.25 
 
*Interpretive criteria currently not standardized .studies show that MICs above 
2µg/ml are associated with treatment failure and < 2µg/ml with clinical cure. 
All the isolates in the study were sensitive to Amphotericin B and were in the 
MIC range of 0.25 to 1µg/ml.  
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TABLE 10 
MINIMUM INHIBITORY CONCENTRATION OF ITRACONAZOLE 
TODIFFERENT MOLDS BY BROTH DILUTION METHOD 
SPECIES NUMBER SENSITIVE 
(MIC<8µg/ml)*
 
RESISTANT  
(MIC 
>8µg/ml) 
MEAN 
MIC 
(µg/ml) 
ATCC A.flavus 
204304 
1 1 
(100%) 
- 
 
0.25 
A.flavus 20 20 
(100%) 
- 
 
0.125 
Rhizopus spp 6 6 
(100%) 
- 
 
0.25 
A.fumigatus 5 5 
(100%) 
- 
 
0.0313 
A.niger 3 3 
(100%) 
- 
 
0.125 
A.nidulans 1 1 
(100%) 
- 
 
0.5 
A.clavatus 1 1 
(100%) 
- 
 
0.25 
Penicillium spp. 1 1 
(100%) 
- 
 
0.125 
Paecilomyces 
variotii. 
1 1 
(100%) 
- 
 
0.25 
 
*Interpretive criteria currently not standardized .Studies show that MICs above 
8 µg/ml are associated with treatment failure and < 8 µg/ml with clinical cure. 
All isolates were universally sensitive to Itraconazole by broth dilution method 
and were in the MIC range of 0.0313 to 0.5. 
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TABLE 11 
DISK DIFFUSION FOR FILAMENTOUS FUNGI FOR 
AMPHOTERICIN B 
SPECIES NUMBER S(ZONE>15 
mm) 
SDD/I(Zone 
13-14 mm) 
R(Zone<12 
mm) 
ATCC 
A.flavus204304  
1 1 
(100%) 
- - 
 
A.flavus 20 15 
(75%) 
4 
(20%) 
1(5%) 
 
Rhizopus spp 6 6 
(100%) 
- - 
 
A.fumigatus 5 5 
(100%) 
- - 
 
A.niger 3 3 
(100%) 
- - 
 
A.nidulans 1 1 
(100%) 
- - 
 
A.clavatus 1 1 
(100%) 
- - 
 
Penicillium spp. 1 1 
(100%) 
- - 
 
Paecilomyces 
variotii 
1 1 
(100%) 
- - 
 
 
S=SUSCEPTIBLE;SDD=SUSCEPTIBLE DOSE 
DEPENDENT;R=RESISTANT 
   75 % of the A.flavus were sensitive to Amphotericin B, 5 % were 
resistant and 20% were susceptible dose dependent. All other species were 
universally sensitive to Amphotericin B.  
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TABLE 12 
DISK DIFFUSION FOR FILAMENTOUS FUNGI FOR 
ITRACONAZOLE 
SPECIES NUMBER S 
(ZONE> 
17 mm) 
SDD/I 
(Zone 14-16 
mm) 
RESISTANT 
(Zone<13mm)
ATCC 
A.flavus 
204304 
1 1 
(100%) 
- - 
 
A.flavus 20 18 
(90%) 
2(10%) - 
 
Rhizopus spp 6  6 
(100%) 
- - 
 
A.fumigatus 5 4 
(80%) 
1(20%) - 
 
A.niger 3 3 
(100%) 
- - 
 
A.nidulans 1 1 
(100%) 
- - 
 
A.clavatus 1 1  
(100%) 
- - 
 
Penicillium 
spp. 
1 1 
(100%) 
- - 
 
Paecilomyces 
variotii 
1 1 
(100%) 
- - 
 
 
 Of the20 Aspergillus spp.90% were sensitive to Itraconazole and 10% 
were susceptible dose dependent. 80 % of A.fumigatus was sensitive to 
Itraconazole and 20% was susceptible dose dependent. All other species were  
sensitive to Itraconazole. 
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TABLE 13 
E TEST FOR AMPHOTERICIN B FOR FILAMENTOUS FUNGI 
AMPHOTERICIN  
SPECIES 
 
NUMBER S R MEAN 
MIC 
(µg/ml) 
ATCC A.flavus 204304 1 1 
(100%) 
- 0.5 
A.flavus 20 20 
(90%) 
 
- 0.25 
Rhizopus spp 6 6 
(100%) 
- 0.5 
A.fumigatus 5 5 
(100%) 
- 
 
0.0313 
A.niger 3 3 
(100%) 
 
- 
0.0313 
A.nidulans 1 1 
(100%) 
 
- 
1 
A.clavatus 1 1 
(100%) 
- 
 
1 
Penicillium spp. 1 1 
(100%) 
- 
 
0.5 
Paecilomyces variotii 1 1 
(100%) 
- 
 
0.0625 
 
 All the isolates were sensitive to Amphotericin B by Epsilometer test 
and MIC range was from 0.0313 to 1. 
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TABLE 14 
AGAR DILUTION MIC FOR ITRACONAZOLE AND 
AMPHOTERICIN B 
AMPHOTERICIN B ITRACONAZOLE SPECIES NO. 
S R MEAN 
MIC 
(µg/ml) 
S R MEAN 
MIC 
(µg/ml) 
ATCC A.flavus 
204304 
1 1 
(100%) 
- 0.5 1 
(100%) 
- 0.25 
A.flavus 20 20 
(100%) 
- 
 
0.5 20 
(100%) 
- 0.125 
Rhizopus spp 
 
6 6 
(100%) 
 0.5 6 
(100%) 
- 0.25 
A.fumigatus 
 
5 5 
(100%) 
- 
 
0.25 5 
(100%) 
- 0.0313
A.niger 3 3 
(100%) 
- 
 
0.125 3 
(100%) 
- 0.125 
A.nidulans 
 
1 1 
(100%) 
- 
 
1 1 
(100%) 
- 0.5 
A.clavatus 
 
1 1 
(100%) 
- 
 
1 1 
(100%) 
- 0.25 
Penicillium 
spp. 
1 1 
(100%) 
- 0.5 1 
(100%) 
- 0.125 
Paecilomyces 
variotii 
1 1 
(100%) 
- 0.25 1 
(100%) 
- 0.25 
 
 All isolates were sensitive to Itraconazole and Amphotericin B by 
agar dilution method. 
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                                                   TABLE 15 
COMPARISON OF DISK DIFFUSION, E TEST AND AGAR DILUTION 
FOR AMPHOTERICIN B WITH MICROBROTH REFERENCE 
METHOD 
Disk diffusion E test Agar 
dilution 
SPECIES 
(N) 
Broth 
dilution 
(S) M M VM M VM M VM 
ATCC A.flavus 
204304(1) 
1 - - - - 
 
- - - 
A.flavus(20) 20 4 
(20
%) 
1 
(5%)
- 
 
- - - - 
Rhizopus 
spp(6) 
6 
 
- - - - - - - 
A.fumigatus(5) 5 - - - 
 
- - - - 
A.niger(3) 3 - - - 
 
- - - - 
A.nidulans(1) 1 - - - 
 
- - - - 
A.clavatus(1) 1 - - - 
 
- - - - 
Penicillium 
spp.(1) 
1 
 
- - - - - - - 
Paecilomyces 
variotii(1) 
1 - - - - - - - 
 
m=minor error; M=Major error ; VM=Very major error 
 Minor error: Shifts between susceptible and susceptible dose 
dependent or between resistant and susceptible dose dependent. 
 Major error: Isolate resistant by other methods but susceptible by broth 
Dilution.  
 Very major error: Broth dilution shows resistance and others show as 
sensitive 
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TABLE 16 
COMPARISON OF DISK DIFFUSION, AND AGAR DILUTION FOR 
ITRACONAZOLE WITH MICROBROTH REFERENCE METHOD 
Disk diffusion Agar 
dilution 
SPECIES Broth dilution
(S) 
M M VM 
 
M VM 
ATCC A.flavus 
204304(1) 
1 - - - - - 
A.flavus 
(20) 
20 2 
(10%)
- - 
 
- - 
Rhizopus spp(6) 6 
 
- - - - - 
A.fumigatus 
(5) 
5 1 
(20%)
- - 
 
- - 
A.niger 
(3) 
3 - - - 
 
- - 
A.nidulans 
(1) 
1 - - - 
 
- - 
A.clavatus 
(1) 
1 - - - 
 
- - 
Penicillium spp.(1) 1 
 
- - - - - 
Paecilomyces 
variotii 
(1) 
1 - - - - - 
 
 m=minor error; M=Major error; VM=Very major error. 
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P=0.522(not significant) 
 
 
 
 
P=0.013 
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Rhizopus 
spp, 13.90%
A.fumigatus,  11.60
%
A.niger, 6.90%
A.nidulans, 2.30%
A.clavatus, 2.30% A.flavus, 46.50%
Penicillium 
spp., 2.30%
Paecilomyces, 2.30
%
12.ETIOLOGICAL AGENTS OF CFRS 
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PATIENT WITH CGFRS : NOTE THE GRANULOMATOUS SWELLING IN LEFT MAXILLA 
 
 
 
 
 
 
 
 
 
 
 
 
CT SCAN SHOWING LEFT MAXILLARY SIMUSITIS NOTE SINUS WALL EROSION 
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FESS SHOWING ALLERGIC MUCIN WITH POLYP. 
 
 
 
 
 
 
 
 
 
 
 
 
10X MAGNIFICATION OF 10% KOH SHOWING HYPHAL ELEMENTS 
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(40X MAGNIFICATION) 10% KOH SHOWING BROAD PAUCISEPTATE HYPHAE WITH OBTUSE 
ANGLE BRANCHING 
 
 
 
 
 
 
 
 
 
 
 
10% KOH SHOWING SLENDER SEPTATE HYPHAE WITH ACUTE ANGLE BRANCHING 
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H&E SECTION SHOWING GRANULOMATOUS REACTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAS SECTION SHOWING SEPTATE SLENDER HYPHAE WITH ACUTE ANGLE BRANCHING 
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H&E SHOWING HYPHAL FORMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
GIEMSA STAIN OF A FUNGAL BALL 
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Aspergillus niger (INSERTMICROSCOPIC PICTURE) 
 
 
 
 
 
 
 
 
 
 
 
 
Aspergillus flavus (INSERTMICROSCOPIC PICTURE) 
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Penicillium spp (INSERTMICROSCOPIC PICTURE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    Aspergillus clavatus (INSERTMICROSCOPIC PICTURE) 
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                                                         Aspergillus versicolor 
 
 
 
 
 
 
 
 
 
 
 
Paecilomyces variotii 
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Rhizopus spp  
 
 
 
 
 
 
 
 
 
 
 
 
 
Aspergillus nidulans (NOTE : HULLE CELLS) 
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Aspergillus fumigatus 
 
 
 
 
 
 
 
 
 
 
 
 
MICROBROTH DILUTION FOR ITRACONAZOLE 
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MIC BREAK POINT DETERMINATION 
 
 
 
 
 
 
 
 
 
 
 
 
MIC DETERMINATION FOR AMPHOTERICIN B 
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AGAR DILUTION SUSCEPTIBILITY TESTING 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISK DIFFUSION FOR ITRACONAZOLE AND AMPHOTERICIN B 
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E TEST FOR Aspergillus niger 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLEISTOTHECIA OF A.nidulans 
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DISCUSSION 
 Fungal Rhinosinusitis is a increasingly recognized entity among cases of  
chronic rhinosinusitis.The importance is increasing due to the morbidity and 
mortality caused by FRS.This study was conducted among 380 cases of 
Chronic Rhinosinusitis who underwent Functional endoscopic sinus surgery 
and Diagnostic nasal endoscopy at the Upgraded Institute of 
Otorhinolaryngology during the study period from January 2010 to June 2011. 
80 cases which fulfilled the inclusion criteria were included in the study. Of the 
80 cases, 43 cases were recognized as chronic Fungal Rhinosinusitis. Overall 
incidence of FRS was 11.3%. Shiv sekar chatterjee et al, 2009 have   recorded 
an incidence of FRS to be 5-15 %6  
 Of the total 43 cases  of  fungal sinusitis( table 1),22(51% )were in the 
age group of 21-40(young adults).An almost equal number 18 patients (41.8%) 
were in the age group of 41-60(middle age) and a minor number of patients(3) 
in the age group>60(6.9%).AFS predominated in the 21-40 age group(62%) 
.This is similar to the observations made by Carrie A Roller et al and 
Chakrabarti et al who have observed that the disease predominated in young 
adults53,54. This can be attributed to the fact that young adults who commonly 
go to the field frequently get mucosal injuries of paranasal sinuses and acquire 
the agent from the area of work, travel and ecology.In contrast to the popular 
belief that AFS is commonly observed in hot and dry climate,it is now reported 
more in hot and humid climate of south India105,106.CIFRS predominated in the 
41-60 age group (63%).All cases of Fungal ball and Chronic granulomatous 
fungal sinusitis were clustered in the age group of 41-60(middle age) . 
 
 
 
91
Shivsekar chatterjee et al, 2009 has also made similar observations that 
invasive sinusitis is more common in middle aged and elderly due to high 
prevalence of risk factors like diabetes.6 In contrast, maximum number of cases 
of non fungal sinusitis were in the age group of 41-60(54%). 
A Slight female predominance was noted in sinusitis of fungal etiology 
(55.8%) whereas males predominated in non FRS group (51.4%) (Table 
1).However this gender difference was not statistically significant. (p=0.522). 
This is in contrast to the observations made by Shiv sekar et al 62009who 
observed a male predominance in developing CFRS.          
Majority of patients of CFRS presented with nasal block (90.6%) as the 
predominant complaint(Table 2) ,though Headache predominated as the 
presenting complaint(97%) in NFRS. Headache was the presenting complaint 
in only 69.7 % of the people with fungal sinusitis. Symptoms like proptosis, 
facial puffiness, tinnitus, diminished vision, altered sensorium, speech 
disturbances and nerve palsies were more common in CFRS than in nonfungal 
CRS probably due to the erosive and invasive nature of the causative fungi. 
Recurrent respiratory tract infection was seen in 83.7% and 65% of CFRS and 
FRS of non fungal etiology. This differs slightly from the study done by Tekin 
Karsligil et al25,2008 where headache and nasal block both predominated in the 
CFRS group (93.9%) . Other throat and laryngeal complications were present 
more in FRS than non FRS(63.6%)25.This data is similar to the observations 
made in our study. 
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In Non FRS group, 31 cases, (84%) involved all sinuses,i.e,pansinusitis. 
(Table 3)In contrast, only 58% was pansinusitis in CFRS group. The next 
common was bilateral Maxillary sinusitis (14%).Bilateral ethmoid and bilateral 
sphenoid sinus alone was involved in 7% of cases each. Unilateral distribution 
was seen only in case of maxillary sinus which constituted 14.3 % of cases. In 
statistical analysis, p<0.05 was obtained. So, it is a statistically significant fact 
that NFRS commonly presented as pansinusitis whereas FRS can also affect 
only a single sinus often .Similar findings have been recorded by Tekin 
Karsligil et al252008 and Shiv sekar chatterjee et al6,2009 who have recorded 
pansinusitis as the commonest occurrence (79%) in cases of FRS. Tajen et al107 
have also observed that fungi may cause inflammation in even only one sinus 
also. 
Among the cases of  proven  chronic fungal rhinosinusitis(n=43),   29 
cases ,i.e, 67% were allergic fungal sinusitis,2 cases,i.e 5 % were fungal ball ,4 
cases,i.e,9% were chronic granulomatous sinusitis and 8 cases ,i.e,19 % were 
chronic invasive sinusitis .(Table 4) Occurrence of Allergic fungal sinusitis 
predominated (67%) when compared to other categories. This is similar to the 
study done by Rajiv .C. Michael et al ,2008 who has reported 63% due to 
allergic fungal disease 22 and Ponikau et al 5 ,1999 who diagnosed allergic FRS 
in 93% of the patients by advanced methods of  sample collection and 
processing. This is in contrast to the results by Chakrabarthy et al60 1992 and 
Panda et al 61 ,1998 who have reported lesser numbers as affected by allergic 
fungal sinusitis.  Alphin et al,Houser et al and Schubert et al have observed that 
the original incidence is not known and that further studies are required for 
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confirmation .64,62,63 In the 8 chronic invasive  fungal sinusitis, 6,i.e. 75% were 
proven sinusitis and 2 cases, i.e,25% was Probable fungal sinusitis.(10% KOH 
positive, culture negative). 
In the 43 chronic fungal rhinosinusitis cases, Hyperglycemia was noted 
as a risk factor in 8 cases(18.6%)(Table 5).When comparing chronic invasive 
rhinosinusitis and other subtypes, Hyperglycemia was observed as a risk factor 
in 75% (6 of 8 cases)of Chronic Invasive Rhinosinusitis and the same risk 
factor was observed in only 6 % of other subtypes.(p=0.002) This shows the 
increased tendency of fungal infections to occur in a more invasive form if 
there is underlying hyperglycemia due to uncontrolled diabetes. Varying data 
are available regarding the existence of hyperglycemia as a risk factor for 
development of the disease. Michael et al,2008 reported uncontrolled diabetes 
in 38.8% of cases of invasive fungal sinusitis22 and they have suggested that the 
study population may have undiagnosed  diabetes mellitus since diabetes is 
known to be extremely common in India. Mohapatra et al 65, 2010, has 
observed that hyperglycemia was noted in 44.8 % of cases . Hassan H 
Ramadan et al66 1995 ,Lansford BK et al671995, Anselmo-Lima WT et al 68, 
2004,LR Patel et al 69,2004,have also observed hyperglycemia as a significant 
risk factor for invasive sinusitis. Diabetes causes increased chance of fungal 
infection because of impaired neutrophil function17,21. Diabetes atlas 2011 by 
International Diabetes Federation has observed that the current number of 
people affected by Diabetes in India is 61 Million and is expected to rise to 100 
Million by 2030 unless preventive measures are taken.They have further 
predicted that by 2030,one in every 10 adults will have diabetes and 4 in every 
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5 diabetics will be in the working age group 40-59 years.103.So , increased 
vigilance will be needed to identify fungal rhinosinusitis in Diabetes  in the 
future. 
Asthma/Chronic Eczema was noted in 46% of other categories(which 
includes AFS,CGFRS and FB)(Table 5). 16 patients of the 29 patients (55%) 
who had Allergic fungal sinusitis had given a history of Asthma and /or 
Chronic eczema. (p<0.001)This was found to be statistically significant 
implying that asthma and other atopic illnesses were significantly associated 
with AFS. Asthma and associated atopic illnesses were noted in 49.1% of 
patients with AFS in a study done by Suraiye.H.Al-Dousary etal, 200859, 50% 
by Manning et al 15and 64% by Schubert et al63. 
19 patients, i.e, 65 % were diagnosed in stage 3 of the disease whereas 
34.4% were diagnosed in stage 4(Table 6).This showed that most patients 
presented to the healthcare facility in fairly advanced stage of the disease. 
Lildholdt et al 71,1997and Laila .M.Telmisani et al72 2009 predicted that the 
recurrence rate increased significantly with increase in grade of the disease, 
suggesting that grading system could be used for prediction of recurrence of 
nasal polyps. Overall recurrence (previous surgery for sinusitis) in our study 
was 51.7%.Recurrence rate was seen more in stage iii of the disease.11 out of 
the total 15 recurrent cases (61%) were in the stage iii of the disease. But this 
association was not statistically significant in our study probably due to loss of 
follow up of patients. (p>0.05) 
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Direct microscopic (10%) KOH mount examination had a sensitivity of 
95.34%.HPE and culture had a sensitivity of 93% and 88.57% respectively. 
(Table 7) Ravikumar et al 73,2004 and Marple BF et al 74,2002 have shown in 
their studies that the sensitivity of HPE was 90% .and 85-90% respectively. 
Though culture is considered as gold standard, culture positivity in this study 
was 88.37%.A few reasons could be the cause for this discrepancy. Excesssive 
maceration of the tissue during FESS or during sample processing can result in 
reduced viability of fungi and also patients already started on antifungals were 
frequently culture negative75.Sensitivity will greatly improve if all the methods 
are combined together. 
Most of the isolates were of a single species (81.3%).4.6 % were mixed 
growth. One of the mixed growth showed both septate and aseptate hyphae in 
direct KOH mount. The other grew both fungi in both DNE and FESS samples. 
Candida spp (C.tropicalis-3 and C.albicans -3) were isolated in 6 
cases.(13.9%).Candida spp are known only as colonizers of the sinuses and 
anterior nares and are known as a very rare cause  of  sinusitis. 
Majority of the fungi isolated were Aspergillus spp. in particular 
A.flavus(46.5%)(Table 8).A.flavus was the commonest isolate in 
AFS(55%),Fungal ball(100%) and Chronic granulomatous disease.(25%).In 
chronic invasive form, however ,Rhizopus spp were the most commmonly 
isolated(50%).A.niger was the 2nd most commonly  isolated in AFRS. Manning 
et al has described 87% of AFRS as due to dematiaceous fungi and the 
remainder due to Aspergillus spp76.But in India, A.flavus is isolated in > 80% 
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of cases of AFRS76,77,78,79,81. This is attributed to the  fact that Aspergillus spp 
are the usual fungi present in the soil and environment of tropical countries like 
India60. Aspergillus species in high concentrations were cultured from straw 
roofs,earthen floor and bedding in houses in a study done by Sandison AT 
104Shiv sekar chatterjee et al describes A.flavus as the main etiological agent  in 
CGFRS also6.This parallels the results of our study. In our study Rhizopus spp. 
predominated in the invasive form of the disease. On the contrary, Chakrabarti 
et al describes A.fumigatus as the commonest fungi causing CIFRS79.  
20 isolates of A.flavus, 6 of Rhizopus spp,4 of A.fumigatus ,3 of A.niger 
and 1 each of A.nidulans, A.clavatus, Penicillium spp. and Paecilomyces 
variotii were taken up for antifungal susceptibility testing for Amphotericin B 
and Itraconazole. ATCC A.flavus 204304 (generously spared by Dr.Shiv 
prakash, Institute of Mycology,PGIMER,Chandigarh)was included in each 
panel as a reference strain. 
 All the fungal isolates were universally sensitive to both Amphotericin 
B and Itraconazole by broth microdilution method(Table 9,10).MIC ranged 
from 0.0313-1 for both the antifungals. The MIC of reference strain was 0.5 
and 0.25 for Amphotericin B and Itraconazole respectively which was well 
within the control limits prescribed by CLSI M38 A33. 
Agar dilution was also done for comparison. The results obtained by 
agar dilution  was comparable to that obtained by microbroth dilution method 
for all the tested 37 isolates (Table 14).E test(Hi Media,Mumbai) was tried for 
Amphotericin B.MICs observed were slightly lower than that observed by 
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broth microdilution method.25 (Table 13) .By contrast, Meletiadis et al. 
compared the results obtained by the E test with the CLSI document M38-A 
and found  that low levels of agreement between the CLSI and the Etest were 
found for most species, especially after 48 h of incubation39. Martin mazielos et 
al 40and Szeley et al38, Etest MICs of Amphotericin B for A. flavus were 
substantially higher than CLSI MICs38,40. Our results correlated if the Etest 
MICs are recorded after 24 h of incubation rather than 48 h or when sufficient 
growth is visible as described by Melitiadis et al39. But, this study is hampered 
by the limited number of isolates available for testing. Further research is 
needed to know the utility of   E test for susceptibility testing for filamentous 
fungi. 
Susceptibility testing was also done using Amphotericin B disks 10µg 
and Itraconazole 10 µg disks(Table 11 and 12). Though percentage of major 
errors was not much (5%), percentage of minor errors was much higher(20%) 
for Aspergillus spp by Amphotericin B(Table 15). So, Amphotericin B disk 
should be used with caution in testing Aspergillus spp.  Zygomycetes have 
given comparable results with broth microdilution and hence Amphotericin B 
disk could be considered for susceptibility testing of zygomycetes. There was 
no major errors noted in Itraconazole disks for testing of filamentous fungi and 
minor error was noted only in insignificant numbers(10%)(Table 16).So, 
Itraconazole disks can be used for susceptibility testing for filamentous fungi. 
This is an expanding area of research with a new document released by CLSI 
quite recently for disk diffusion for moulds and further studies need to be done 
with a large number of isolates to assess the utility of the same. 
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The above results are comparable with the studies done by A.Espinell –
Ingroff,200785, A.Espinell –Ingroff et al,200686,lopez Oviedo et al,2006101 and 
Serrano MC et al ,2004 102who have  noted in their respective studies that  
Itraconazole  10µg  disks are suitable for testing of all species except 
zygomycetes, whereas posoconazole 10µg disks give a better correlation than 
Itraconazole for  testing  Zygomycetes.  They have further noted that lowest 
correlation was noted consistently for Amphotericin B Disk 10 µg (23% minor 
error,3% major error and 1.7% Very Major error noted) and have suggested 
that Amphotericin B be used  for susceptibility testing of  only 
Zygomycetes85,86.Posaconazole disk diffusion was not done in this study, It 
could have been included in  the study for comparison with Itraconazole disk. 
Strong suspicion, meticulous specimen collection & preparation and 
further studies with a long period of follow up and more number of patients are 
required to analyse the impact of fungi in the etiopathogenesis of chronic 
rhinosinusitis. 
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SUMMARY 
 Among the 380 Patients who underwent DNE and/or FESS , 80 patients 
who complied with the inclusion criteria were included under the 
study.43 patients were diagnosed as CFRS, contributing to 11.3% of the 
total cases. 
 Of the CFRS categories, Allergic fungal sinusitis was the most 
predominant contributing to 67 % of the disease. 
 Allergic fungal rhinosinusitis was found more in young adults(21-40) 
(p<0.05)and Invasive fungal sinusitis was found more in the middle 
aged(41-60) . 
 Pansinusitis was the most common presentation in both FRS and non 
FRS group(58% and 84%).Isolated sinus involvement was observed 
more commonly in FRS than NFRS. Among the FRS, isolated 
maxillary, isolated sphenoid and isolated ethmoid fungal sinusitis (14%, 
7% and 7% respectively) were commonly observed . 
 Nasal block was the most common presentation(90.6%) in CFRS  
 Hyperglycemia was observed as a statistically significant associated 
risk factor (75%)for the development of invasive form of fungal 
sinusitis . 
 Asthma and other atopic illnesses were significantly 
associated(55%) with the development of allergic fungal 
rhinosinusitis.  
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 Among the patients of AFRS, 67% presented late to the health care 
facility, i.e stage III and Recurrence was noted in 51.7% of AFRS 
patients. 
 Direct microscopy was highly sensitive in clinching the diagnosis of 
CFRS in 95.34% of cases when compared to HPE and culture.  
 A.flavus was the most common isolate in AFRS(55%), FB(100%) and 
CGFRS(25%) and Rhizopus spp. was the most common isolate in 
CIFRS(50%). 
 All isolates were sensitive to Amphotericin B and Itraconazole by broth 
microdilution method &agar dilution . 
 E test can also be used with caution for susceptibility testing of 
filamentous fungi with meticulous Quality control testing. 
 Disk diffusion method with Amphotericin B (10 µg disk) was found to 
be reliable for susceptibility testing of Zygomycetes as it is easy and 
suitable for routine testing in laboratories.Similarly,Itraconazole 10µg 
disk was found to be reliable for susceptibility testing of all filamentous 
fungi. 
 For life threatening invasive fungal infections, broth microdilution must 
be carried out for Amphotericin B to provide useful information to the 
clinician even if empirical antifungal therapy is already started for the 
patient . 
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CONCLUSION 
Chronic Fungal Rhinosinusitis largely impairs the active functioning of 
the patients in their day to day life and causes a significant morbidity and even 
mortality. This study was undertaken to assess the prevalence of CFRS, to 
isolate and identify the fungi &their sensitivity pattern to standard antifungal 
agents and to study the risk factors favouring CFRS in patients undergoing 
functional endoscopic sinus surgery and diagnostic nasal endoscopy in Rajiv 
Gandhi Government general hospital,Chennai. CFRS was noted in 11% of the 
cases in the present study. 
Categorisation of CFRS is essential and helps to decide the best 
treatment option for the patient. Allergic fungal sinusitis was the most 
common presentation noted(67%)followed by chronic invasive(19%), 
chronic granulomatous (9%)and fungal ball(5%).Patients with uncontrolled 
diabetes are at risk of acquiring invasive form of CFRS. Patients with 
documented asthma and associated atopic illnesses are at an increased risk of 
acquiring AFRS. Aspergillus flavus was most commonly isolated(46.5%) 
followed by Rhizopus spp(13.9%), Aspergillus fumigatus(11.6%), 
A.niger(6.9%), A.clavatus(2.3%),   A.versicolor(2.3%), A.nidulans(2.3%), 
Penicillium spp(2.3%) and Paecilomyces variotii(2.3%). A.flavus was the most 
common isolate in AFRS, FB and CGFRS and Rhizopus spp. was the most 
common isolate in CIFRS. Grave complications like orbital cellulitis, brain 
abscess, orbital granuloma, cavernous sinus thrombosis and cranial nerve 
palsies were seen in this study. Direct microscopy was highly sensitive in 
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clinching the diagnosis of CFRS in 95.34% of cases when compared to HPE 
and culture. Detection rate increased when direct microscopy and culture were 
used in conjunction with histopathological examination. 
Anti fungal sensitivity testing should be done as a routine for all cases 
when feasible as resistant strains are emerging.In this study, all isolates were 
sensitive to Amphotericin B and Itraconazole by broth microdilution method & 
agar dilution. 
Though conventionally, microbroth /agar dilution is done for 
filamentous fungi, in this study E test and disk diffusion, (Amphotericin B 10 
µg disk for Zygomycetes and Itraconazole 10 µg disk for all filamentous 
fungi) were found to be equally good and can be followed for routine testing. 
But, in life threatening invasive fungal infections, it is prudent to do 
microbroth/agar dilution for antifungal susceptibility testing.  
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PROFORMA 
S.NO  :                                                                            IP/OP NO.: 
Name of the patient:                                                       Occupation: 
Age:                                                                                 Sex: 
Address: 
Presenting complaints;                                                         Duration 
Underlying illness(tick when appropriate): 
H/o Asthma 
H/o Aspirin allergy 
H/o Diabetes mellitus 
H/o Chronic Eczema 
H/o COPD 
H/o Uremia/Chronic Kidney disease 
H/o Neoplasm 
H/o Immunosuppressive therapy 
H/o Faciomaxillary Trauma 
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H/o previous nose/ throat /sinus surgery 
PHYSICAL EXAMINATION: 
DNE/FESS: 
BIOLOGICAL PARAMETERS: 
Blood sugar: 
S.urea: 
S.creatinine: 
OTHER INVESTIGATIONS: 
Total WBC count: 
Differential count; 
Absolute eosinophil count: 
X Ray PNS: 
CT PNS: 
MRI PNS: 
Histo pathological examination: 
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MICROBIOLOGICAL EXAMINATION: 
Direct Examination with 10% Potassium hydroxide 
CULTURE: 
Antifungal susceptibility pattern: 
1.Disk diffusion: 
2.MIC:          By Broth dilution: 
            By Agar dilution: 
            By  E test: 
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                                                APPENDIX 
I.10% POTASSIUM HYDROXIDE SOLUTION: 
Potassium hydroxide-10 gm 
Glycerol                    -10 ml 
Distilled water          -80 ml 
To the solution of 10% KOH, 10% glycerol is added to prevent drying. 
The ingredients are mixed and stored at room temperature. 
II. Lactophenol cotton blue stain  
Lactic acid        20 ml 
Phenol       20ml 
Cotton blue (dye)      0.5g 
Glycerol       40ml 
           Distilled water                                                      20ml 
III.MEDIA USED: 
1.SABOURAUD DEXTOSE AGAR WITH ANTIBIOTICS: 
COMPOSITION: 
Peptone                :10 gm 
Dextrose              :40 gm 
Agar                    :20 gm 
Distilled water    :1000 ml 
Gentamicin         :20 mg 
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Final pH was adjusted to 5.6. 
Media preparation: 
        The above ingredients were reconstituted in one litre of distilled water. 
Dissolve the powder in distilled water by boiling. Add Gentamicin is added to 
the boiling medium. The medium was then removed from heating, mixed well 
and then dispersed in tubes and autoclaved at 1210 C for 15 minutes and the 
final pH was adjusted to 5.6.The tubes were cooled in slanted position and later 
the slants were stored in refrigerator. 
2.YEAST NITROGEN BASE AGAR MEDIUM(DEHYDRATED NEDIA, 
Himedia, MUMBAI) 
INGREDIENTS GRAMS/L INGREDIENTS GRAMS/L 
Ammonium sulphate 
L-Histidine 
hydrochloride 
DL-Methionine 
DL-Tryptophan 
Biotin 
Calcium pantothenate 
Folic acid 
Inositol 
Niacin 
Para amino benzoic acid 
Pyridoxine 
hydrochloride 
Riboflavin 
 
5.00 
0.01 
0.02 
0.02 
0.000002 
0.00004 
0.000002 
0.02 
0.0004 
0.0002 
0.0004 
0.0002 
Thiamine hydrochloride 
Boric acid 
Copper sulphate 
Potassium iodide 
Ferric chloride 
Manganese sulphate 
Sodium molybdate 
Zinc sulphate 
Monopotassium 
phosphate 
Magnesium sulphate 
Sodium chloride 
Calcium chloride 
 
0.004 
0.0005 
0.00004 
0.0001 
0.0002 
0.0004 
0.0002 
0.0004 
1.00 
0.50 
0.10 
0.10 
 
       Dissolve 6.7 gms of the media in 100 ml of distilled water. Sterilise by 
filteration and store at 40C. 
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3.MUELLER HINTON AGAR: 
Beef infusion                       : 300 ml 
Casein hydrosylate              : 17.5 gm 
Starch                                   : 1.5 gm 
Agar                                     : 10 gm 
Distilled Water                    : 1000 ml 
 pH                                       : 7.4 
Sterilize by autoclaving at 1210C for 20 minutes. 
4.RPMI 1640(ROSEWALL PARK MEMORIAL INSTITUTE) MEDIA: 
* RPMI  medium         : 10.4 gm 
* MOPS buffer            :34.43 gm 
Dissolve powdered medium in 900 ml distilled water . Add MOPS to a final 
concentration of 0.165 mol/ L and stir until dissolved. While stirring, adjust the 
pH to 7.0 at 250 C. Add additional water to bring medium to a final volume of 
1000 ml. Filter sterilize and store at 40C. 
5. POTATO DEXTROSE AGAR: 
Potato     :200 G              Dextrose:20 G 
Agar       : 20 G 
Water     : 1 Litre 
Boil 200 g of potatoes in 1 litre of water for 60 minutes. Squeeze as much as 
pulp as possible through a fine sieve. Add agar and boil till it dissolves.Add 
dextrose and make upto 1 litre. Dispense in required amounts taking care to 
keep the solids in suspension. Autoclave at 1150C for 30 minutes. Cool to 500C 
and pour into petridishes. 
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ABBREVIATIONS 
  
AFRS   : Allergic Fungal Rhinosinusitis 
CFRS   : Chronic Fungal Rhinosinusitis 
CGFRS  : Chronic Granulomatous Fungal Rhinosinusitis 
CIFRS  : Chronic Invasive Fungal Rhinosinusitis 
CLSI   : Clinical Laboratory Standard Institute 
DMSO  : Dimethyl sulfoxide 
E TEST  : Epsilometer test 
ELISA  : Enzyme  Linked Immunosorbent Assay 
FB   : Fungal ball 
FRS   : Fungal Rhinosinusitis 
GMS   : Gomori Methenamine silver 
H%E   : Haematoxylin and eosin 
HPE   : Histopathological examination 
KOH   : Potassium hydroxide mount 
m   : Minor error 
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M   : Major error 
VM   : Very Major error 
MHA   : Mueller Hinton Agar 
MIC   : Minimum Inhibitory Concentration 
MOPS  : 3N-Morpholino propane sulphonic acid 
MRI   : Magnetic resonance imaging 
NFRS   : Non fungal rhinosinusitis 
PAS   : Periodic acid schiff 
PDA   : Potato Dextrose agar 
PNS   : Paranasal sinus 
RPMI   : Rosewall Park Memorial Institute 
R   : Resistant 
S   : Susceptible 
SDD   : Susceptible Dose Dependent 
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CONSENT FORM 
STUDY TITLE: 
A STUDY ON THE MYCOLOGICAL PROFILE, CATEGORIZATION 
AND ANTIFUNGAL SUSCEPTIBILITY PATTERN OF CHRONIC 
FUNGAL RHINOSINUSITIS IN A TERTIARY CARE HOSPITAL 
STUDY CENTRE: 
     Institute of microbiology, Rajiv Gandhi govt. General hospital, Chennai-03. 
Name:                                                                          Date: 
Age/Sex:                                                                      IP.NO:                                                       
I conform that I understand the purpose of the above study and I have 
the opportunity to ask questions. All my questions and doubts have been 
answered to my satisfaction. I understand that my participation in this study is 
voluntary and I am free to withdraw at any time without giving any reason. I 
understand that the investigator, regulatory authorities and ethical  committees 
will not need my permission, to look at my health records both in respect to 
current study and any further research that be conducted in relation to it. 
I understand that my participation in the study will not affect my 
treatment. I have received information sheet regarding the research.I hereby 
consent to participate in study “A STUDY ON THE MYCOLOGICAL 
PROFILE, CATEGORIZATION AND ANTIFUNGAL SUSCEPTIBILITY 
PATTERN OF CHRONIC FUNGAL RHINOSINUSITIS IN A TERTIARY 
CARE HOSPITAL” conducted at   Institute of microbiology, Rajiv Gandhi 
govt. General hospital, Chennai-03. 
 
Date: 
Place:     Signature/thumb impression of patient 
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1‐nasal block    6:anosmia
2‐nasal discharge    7‐tinnitus 
3‐headache    8‐RRTI 
4‐facial puffiness    9‐OTHERS 
5‐proptosis     
 
 A STUDY ON THE MYCOLOGICAL PROFILE, CATEGORIZATION 
AND ANTIFUNGAL SUSCEPTIBILITY PATTERN OF CHRONIC 
FUNGAL RHINOSINUSITIS IN A TERTIARY CARE HOSPITAL 
 
 
ABSTRACT 
 
 
           Fungal sinusitis is being increasingly recognized in persons of all age 
groups, resulting in great socioeconomic effects. This study was conducted in a 
tertiary care hospital to evaluate the occurrence of Chronic fungal rhinosinusitis in 
patients admitted with  a radiological diagnosis  of rhinosinusitis and undergoing 
diagnostic and therapeutic endoscopic procedures for  the same in atertiary care 
hospital. 
AIM: 
           This study was conducted with the aim to isolate and identify the fungi 
causing chronic fungal rhinosinusitis,to categorise the types of fungal sinusitis,to 
assess the  risk factors favouring fungal involvement of paranasal sinuses ,to study 
the susceptibility pattern of the fungal isolates to standard anti fungal drugs and to 
compare different methods of susceptibility testing for the fungal isolates. 
 
 
 
MATERIALS AND METHODS : 
Sample collection,processing and identification of the fungal isolates were done 
following standard operating procedures.Antifungal susceptibility testing was done 
by Broth microdilution,Agar dilution ,Disk diffusion and E test and the results 
compared. 
RESULTS AND DISCUSSION: 
                CFRS was noted in 11% of the cases in the present study.Allergic fungal 
sinusitis was the most common presentation noted(67%)followed by chronic 
invasive(19%) ,chronic granulomatous (9%)and fungal ball(5%).Patients with 
uncontrolled diabetes are at risk of acquiring invasive form of CFRS. Patients with 
documented asthma and associated atopic illnesses are at an increased risk of 
acquiring AFRS. Aspergillus flavus was most commonly isolated(46.5%) . A.flavus 
was the most common isolate in AFRS, FB and CGFRS and Rhizopus spp. was the 
most common isolate in CIFRS. All isolates were sensitive to Amphotericin B and 
Itraconazole by broth microdilution method &agar dilution .E test can also be used 
with caution for susceptibility testing of filamentous fungi with meticulous Quality 
control testing.Disk diffusion method with Amphotericin B (10 µg disk) was found 
to be reliable for susceptibility testing of Zygomycetes as it is easy and suitable for 
routine testing in laboratories.Similarly,Itraconazole 10µg disk was found to be 
reliable for susceptibility testing of all filamentous fungi. 
 CONCLUSION: 
              CFRS was noted in 11% of the cases in the present study.  Categorisation 
of CFRS is essential and helps to decide the best treatment option for the patient. 
Aspergillus flavus was most commonly isolated .Anti fungal sensitivity testing 
should be done as a routine for all cases when feasible as resistant strains are 
emerging E test and disk diffusion, (Amphotericin B 10 µg disk for Zygomycetes 
and Itraconazole 10 µg disk for all filamentous fungi ) were found to be equally 
good and can be followed for routine testing. But, in life threatening invasive 
fungal infections, it is prudent to do microbroth/agar dilution for antifungal 
susceptibility testing. 
KEY WORDS: Fungal sinusitis, Categories, Susceptibility testing 
